

## AUTHOR INDEX FOR VOLUME 18

## A

- Adler, A. *See Scheibel*, 320
- Agrawal, Krishna C. *See Preidecker, Sartorelli, and Moore*, 507
- Agresti, Alessandro, Buffoni, Franca, Kaufman, Joyce J., and Petrongolo, Carlo. Structure-Activity Relationships of Eseroline and Morphine: *Ab Initio* Quantum-Chemical Study of the Electrostatic Potential of the Interaction Energy with Water, 461
- Aitio, Antero. *See Felton, Ketley, Jakoby, Bend, and Nebert*, 559
- Anjaneyulu, Kowluru. *See Couturier, Sener, and Malaisse*, 243
- Albuquerque, Edson X., Tsai, Ming-Cheng, Aronstam, Robert S., Eldefrawi, Amira T., and Eldefrawi, Mohyee E. Sites of Action of Phencyclidine. II. Interaction with the Ionic Channel of the Nicotinic Receptor, 167; *See also* Tsai, Aronstam, Eldefrawi, Eldefrawi and Triggle, 159; Aronstam, Eldefrawi, Eldefrawi, Jim, and Triggle, 179; Spivak, 384
- Armstrong, Joyce A., Marks, Gerald S., and Armstrong, Paul W. Absence of Metabolite Formation during Nitroglycerin-Induced Relaxation of Isolated Blood Vessels, 112
- Armstrong, Paul W. *See Armstrong and Marks*, 112
- Aronstam, Robert S., Eldefrawi, Mohyee E., Eldefrawi, Amira T., Albuquerque, Edson X., Jim, Kam F., and Triggle, David J. Sites of Action of Phencyclidine. III. Interactions with Muscarinic Receptors, 179; *See also* Tsai, Albuquerque, Eldefrawi, Eldefrawi, and Triggle, 159; Albuquerque, Tsai, Eldefrawi, and Eldefrawi, 167
- Asakura, Mikio. *See Shima, Kawashima, Hirai, and Kouyama*, 45
- Askari, Amir. *See Huang*, 53
- Aten, Raymond R. *See Dickson and Eisenfeld*, 215
- Attie, M. F. *See Brown, Reen, Gardner, Kebabian, and Aurbach*, 335
- Aurbach, G. D. *See Brown, Attie, Reen, Gardner, and Kebabian*, 335

## B

- Baldwin, Sheryl, Kier, Lemont B., and Shillady, Donald. Approximate Molecular Potentials of Mescaline Analogues in a Study of Similarities to 5-Hydroxytryptamine, 455
- Barbin, G., Palacios, J. M., Roderigas, E., Schwartz, J. C., and Garbarg, M. Characterization of the High-Affinity Binding Sites of [<sup>3</sup>H]Histamine in Rat Brain, 1
- Baron, Jeffrey. *See Taira, Greenspan, Kapke, and Redick*, 304
- Barone, Vincenzo, Lelj, Francesco, and Russo, Nino. Conformational Analysis of *N*-( $\beta$ -Actoxyethyl)Pyridinium Ion: Comparisons with Acetylcholine, 331
- Beerman, Terry A. *See Woyrnarowski*, 491
- Bend, John R. *See Felton, Ketley, Jakoby, Aitio, and Nebert*, 559
- Boatman, Rodney J. *See Poland, Mak, Glover, Ebetino, and Kende*, 571
- Braswell, Leon M. *See Pang, Chang, Sommer, and Miller*, 84
- Bresnick, Edward, Hassuk, Bruce, Liberator, Paul, Levin, Wayne, and Thomas, Paul E. Nucleolar Cytochrome P-450, 550
- Browning, Edward T. *See Groppi*, 427
- Brown, E. M., Attie, M. F., Reen, S., Gardner, D. G., Kebabian, J., and Aurbach, G. D. Characterization of Dopaminergic Receptors in Dispersed Bovine Parathyroid Cells, 335
- Buffoni, Franca. *See Agresti, Kaufman, and Petrongolo*, 461
- Butcher, Reginald W. *See Nemecek and Wells*, 57
- Chang, Larry. *See Pang, Braswell, Sommer, and Miller*, 84
- Changuex, Jean-Pierre. *See Waksman and Roques*, 20
- Chao, Haiyen. *See Chung*, 543
- Charnock, J. S., Gibson, R. A., McMurchie, E. J., and Raison, J. K. Changes in the Fluidity of Myocardial Membranes during Hibernation: Relationship to Myocardial Adenosinetriphosphatase Activity, 476
- Chello, Paul L., Sirotinak, Francis M., and Dorick, Diane M. Alterations in the Kinetics of Methotrexate Transport during Growth of L1210 Murine Leukemia Cells in Culture, 274
- Chen, Beatrice P. *See Wei and Rice*, 497
- Chuang, De-Maw, Kinnier, William J., Farber, Len, and Costa, Ermino. A Biochemical Study of Receptor Internalization during  $\beta$ -Adrenergic Receptor Desensitization in Frog Erythrocytes, 348
- Chuang, Linda F. *See Kawahata, Holmberg, Osburn, and Chuang*, 503
- Chuang, Ronald Y. *See Kawahata, Holmberg, Osburn, and Chuang*, 503
- Cheng, Yung-Chi. *See Caradonna*, 573
- Chrystal, Ewan J. T., Koch, Ronald L., and Goldman, Peter. Metabolites from the Reduction of Metronidazole by Xanthine Oxidase, 105
- Chung, Leland W. K. and Chao, Haiyen. Neonatal Imprinting and Hepatic Cytochrome P-450 I. Comparison of Testosterone Hydroxylation in a Reconstituted System between Neonatally Imprinted and Nonimprinted Rats, 543
- Cooper, Dermot M. F., Londos, Constantine, and Rodbell, Martin. Adenosine Receptor-Mediated Inhibition of Rat Cerebral Cortical Adenylate Cyclase by a GTP-Dependent Process, 598
- Corcoran, G. B., Mitchell, J. R., Vaishnav, Y. N., and Horning, E. C. Evidence That Acetaminophen and *N*-Hydroxyacetaminophen Form a Common Arylating Intermediate, *N*-Acetyl-*p*-Benzoquinoneimine, 536
- Costa, Erminio. *See Chuang, Kinnier, and Farber*, 348
- Couturier, Etienne, Sener, Abdullah, Anjaneyulu, Kowluru, and Malaisse, Willy J. Inhibition by Quinine of Insulin Release and Calcium Ionophoresis, 243
- Dahlig, Ewa. *See Paterson, Lau, and Cass*, 40
- Danenberg, Peter V. *See Sarraf, Tone, and Heidelberger*, 148
- Davis, James N., Olender, Edward, Maury, Wendy, and McDaniel, Robert.  $\alpha$ -Adrenergic Regulation of Cholinergic Responses in Rat Parotid Acinar Cells, 356
- Dickson, Robert B., Aten, Raymond R., and Eisenfeld, Arnold J. Receptor-Bound Estrogens and Their Metabolites in the Nucleus of Isolated Rat Liver Parenchymal Cell, 215
- DiStefano, Victor. *See Ducis*, 438; 447
- Dorick, Diane M. *See Chello and Sirotinak*, 274
- Duch, David S., Edelstein, Mark P., and Nichol, Charles A. Inhibition of Histamine-Metabolizing Enzymes and Elevation of Histamine Levels in Tissues by Lipid-Soluble Anticancer Folate Antagonists, 100
- Ducis, Ilze, and DiStefano, Victor. Evidence for a Serotonin Uptake System in Isolated Bovine Pinealocyte Suspensions, 438
- Ducis, Ilze, and DiStefano, Victor. Characterization of Serotonin Uptake in Isolated Bovine Pinealocyte Suspensions, 447
- Duell, Elizabeth A. Adenosine-Induced Alterations in the Adenosine 3':5'-Monophosphate Levels in Mammalian Epidermis, 49
- Dybing, Erik. *See Wirth, von Bahr, and Thorgeirsson*, 117

## C

- Caradonna, Salvatore J. and Cheng, Yung-Chi. The Role of Deoxyuridine Triphosphate Nucleotidohydrolase, Uracil-DNA Glycosylase, and DNA Polymerase  $\alpha$  in the Metabolism of FUDR in Human Tumor Cells, 573
- Cass, Carol E. *See Paterson, Lau, and Dahlig*, 40

## E

- Ebetino, Frank H. *See Poland, Mak, Glover, Boatman, and Kende*, 571
- Edelstein, Mark P. *See Duch and Nichol*, 100

- Eisenfeld, Arnold J. *See* Dickson and Aten, 215  
 Eldefrawi, Amira T. *See* Tsai, Albuquerque, Aronstam, Eldefrawi, and Triggle, 159; Albuquerque, Tsai, Aronstam, and Eldefrawi, 167; Aronstam, Eldefrawi, Albuquerque, Jim, and Triggle, 179  
 Eldefrawi, Mohyee E. *See* Tsai, Albuquerque, Aronstam, Eldefrawi, and Triggle, 159; Albuquerque, Tsai, Aronstam, and Eldefrawi, 167; Aronstam, Eldefrawi, Albuquerque, Jim, and Triggle, 179  
 Erdoz, Joseph J. and Maguire, Michael E. Independent Desensitization of  $\beta$ -Adrenergic Receptor-Regulated Magnesium Transport and Cyclic AMP Accumulation, 379

## F

- Fain, John N. *See* García-Sáinz, 72  
 Fairchild, Edward H. *See* Tracy, Lucas, and Webster, 313  
 Farber, Len. *See* Chuang, Kinnier, and Costa, 348  
 Faulkner, Robert. *See* Huang, 267  
 Felton, James S., Ketley, Jeanne N., Jakoby, William B., Aitio, Antero, Bend, John R., and Nebert, Daniel W. Hepatic Glutathione Transferase Activity Induced by Polycyclic Aromatic Compounds. Lack of Correlation with the Murine Ah Locus, 559  
 Freychet, Pierre. *See* Kitabgi, Poustis, Granier, Van Rietschoten, Rivier, and Morgat, 11

## G

- Garbarg, M. *See* Barbin, Palacios, Rodergas, and Schwartz, 1  
 García-Sáinz, J. Adolfo and Fain, John N. Effect of Adrenergic Amines on Phosphatidylinositol Labeling and Glycogen Synthase Activity in Fat Cells from Euthyroid and Hypothyroid Rats, 72  
 Gardner, D. G. *See* Brown, Attie, Reen, Kebabian, and Aurbach, 335  
 Gibson, R. A. *See* Charnock, McMurchie, and Raison, 476  
 Glazer, Robert I. and Hartman, Kathleen D. Evidence That the Inhibitory Effect of Adenosine, but Not Cordycepin, on the Methylation of Nuclear RNA is Mediated by S-Adenosylhomocystein Hydrolase, 483  
 Glover, Edward. *See* Poland, Mak, Boatman, Ebetino, and Kende, 571  
 Goldman, Peter. *See* Chrystal and Koch, 105  
 Gordon, Paul B. *See* Seglen, 468  
 Graham, Doyle G. *See* Patton, Rosen, Rauckman, Small, and Ziegler, 151  
 Granier, Claude. *See* Kitabgi, Poustis, Van Rietschoten, Rivier, Morgat, and Freychet, 11  
 Greco, William R. and Hakala, Marie T. Biochemical Pharmacology of Lipophilic Diaminopyrimidine Antifolates in Mouse and Human Cells *in Vitro*, 521  
 Greenspan, Phillip. *See* Taira, Kapke, Redick, and Baron, 304  
 Groppi, Vincent E. Jr., and Browning, Edward T. Norepinephrine-Dependent Protein Phosphorylation in Intact C-6 Glioma Cells. Analysis by Two-Dimensional Gel Electrophoresis, 427  
 Gupta, Radhey S., Krepinsky, Jiri J., and Siminovitch, Louis. Structural Determinants Responsible for the Biological Activity of (—)-Emetine, (—)-Cryptolepine, and (—)-Tylocrebrine: Structure-Activity Relationship among Related Compounds, 136  
 Gurtsoo, Hira L. Genetic Expressions of Aflatoxin B<sub>1</sub> Metabolism: Effects of 3-Methylcholanthrene and 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin on the Metabolism of Aflatoxins by B<sub>1</sub> and B<sub>2</sub> by Various Inbred Strains of Mice, 296

## H

- Hakala, Marie T. *See* Greco, 521  
 Hanin, Israel. *See* Mantione, 28  
 Hanley, Michael R., Lee, C. M., Jones, Lynne M., and Michell, Robert H. Similar Effects of Substance P and Related Peptides on Salivation and on Phosphatidylinositol Turnover in Rat Salivary Glands, 78

- Harrelson, Willard G. Jr., *See* Wolf, Nastainczyk, Philpot, Kalyanaraman, and Mason, 553  
 Hartman, Kathleen D. *See* Glazer, 483  
 Hassuk, Bruce. *See* Bresnick, Liberator, Levin, and Thomas, 550  
 Heidelberger, Charles. *See* Sarraf, Tone, and Danenberg, 148  
 Herz, Albert. *See* Schulz, Wuster, and Krenss, 395  
 Hirai, Masanao. *See* Shima, Kawashima, Asakura, and Kouyama, 45  
 Holmberg, Charles A. *See* Kawahata, Osburn, Chuang, and Chuang, 503  
 Holz, Ronald W. Correlation of the Effects of Bretylium, Guanethidine, and *N,N*-Diisopropyl-*N'*-Isoamyl-*N'*-Diethylaminoethylurea (P-286) on the H<sup>+</sup> Electrochemical Gradient across the Chromaffin Granule Membrane and on Chromaffin Granule Function, 606  
 Horning, E. C. *See* Corcoran, Mitchell, and Vaishnav, 536  
 Huang, Rose H. and Faulkner, Robert. Lipid-Protein Interactions in the Multiple Forms of Monoamine Oxidases: Lipases as Probes Using Purified Intact Rat Brain Mitochondria, 267  
 Huang, Wu-Hsiung and Askari, Amir. Ouabain-Induced Changes in the Tertiary and the Quaternary Conformations of (Na<sup>+</sup> + K<sup>+</sup>)-Activated Adenosine Triphosphatase, 53

## J

- Jackson, Robert C. Modulation of Methotrexate Toxicity by Thymidine: Sequence-Dependent Biochemical Effects, 281  
 Jakoby, William B. *See* Felton, Ketley, Aitio, Bend, and Nebert, 559  
 Jergil, Bengt. *See* Schelin, Tunek, and Jerstrom, 529  
 Jerström, Bengt. *See* Schelin, Tunek, and Jergil, 529  
 Jim, Kam F. *See* Aronstam, Eldefrawi, Eldefrawi, Albuquerque, and Triggle, 179  
 Johnson, Eric F. *See* Liem and Muller-Eberhard, 565  
 Jones, Lynne M. *See* Hanley, Lee, and Michell, 78

## K

- Kalyanaraman, B. *See* Wolf, Harrelson, Nastainczyk, Philpot, and Mason, 553  
 Kapke, Gordon F. *See* Taira, Greenspan, Redick, and Baron, 304  
 Katzenellenbogen, Benita S. *See* Pavlik, 406  
 Kaufman, Joyce J. *See* Agresti, Buffoni, and Petrongolo, 461  
 Kawahata, Russell T., Holmberg, Charles A., Osburn, Bennie L., Chuang, Linda F., and Chuang, Ronald Y. Effect of 6-Mercaptopurine Ribonucleotides on DNA-Dependent RNA Polymerase Activity, 503  
 Kawashima, Yoshiko. *See* Shima, Hirai, Asakura, and Kouyama, 45  
 Kebabian, J. *See* Brown, Attie, Reen, Gardner, and Aurbach, 335  
 Kende, Andrew S. *See* Poland, Mak, Glover, Boatman, and Ebetino, 571  
 Ketley, Jeanne N. *See* Felton, Jakoby, Aitio, Bend, and Nebert, 559  
 Kier, Lemont B. *See* Baldwin and Shillady, 455  
 Kim, Ryung-soon (Song), LaBella, Frank S., Zunza, Hilda, Zunka, Federika, and Templeton, John F. Progesterone Derivatives that Bind to the Digitalis Receptor: Structure-Activity Relationships, 402  
 Kinnier, William J. *See* Chuang, Farber, and Costa, 348  
 Kitabgi, Patrick, Poustis, Claudine, Granier, Claude, Van Rietschoten, Jurphaas, Rivier, Jean, Morgat, Jean-Louis, and Freychet, Pierre. Neurotensin Binding to Extraneural and Neural Receptors: Comparison with Biological Activity and Structure-Activity Relationships, 11  
 Kober, Anita, Olsson, Ylva, and Sjöholm, Ingvar. Binding of Drugs to Human Serum Albumin. XIV. The Theoretical Basis for the Interaction between Phenytoin and Valproate, 237  
 Kober, Anita and Sjöholm, Ingvar. The Binding Sites on Human Serum Albumin for Some Nonsteroidal Antiinflammatory Drugs, 421  
 Koch, Ronald L. *See* Chrystal and Goldman, 105

## N

- Koontz, John N. and Wicks, Wesley D. Cytotoxic Effects of Two Novel 8-Substituted Cyclic Nucleotide Derivatives in Cultured Rat Hepatoma Cells, 65
- Kouyama, Hiroshi. *See Shima, Kawashima, Hirai, and Asakura*, 45
- Krenss, Heinz. *See Schulz, Wüster, and Herz*, 395
- Krepinsky, Jiri L. *See Gupta and Siminovich*, 136
- Kunze, Kent L. *See Ortiz de Montellano and Mico*, 602
- Kwok, Y. C. and Moore, G. J. Affinity Labeling of Angiotensin II Receptors in the Isolated Rat Uterus with Photolabile Antagonist, 210
- L
- Labella, Frank S. *See Kim, Zunza, Zunka, and Templeton*, 402
- Lau, Christopher and Slotkin, Theodore A. Regulation of Ornithine Decarboxylase Activity in the Developing Heart of Euthyroid or Hyperthyroid Rats, 247
- Lau, Eda Y. *See Paterson, Dahlig, and Cass*, 40
- Lee, C. M. *See Hanley, Jones, and Michell*, 78
- Leighton, H. J. *See Waggoner and McDermed*, 91
- Lelj, Francesco. *See Barone and Russo*, 331
- Levin, Wayne. *See Bresnick, Hassuk, Liberator and Thomas*, 550
- Liberator, Paul. *See Bresnick, Hassuk, Levin, and Thomas*, 550
- Liem, Heng H., Muller-Eberhard, Ursula, and Johnson, Eric F. Differential Induction by 2,3,7,8-Tetrachlorodibenzo-p-dioxin of Multiple Forms of Rabbit Microsomal Cytochrome P-450: Evidence for Tissue Specificity, 565
- Londos, Constantine. *See Cooper and Rodbell*, 598
- Lucas, Samuel V. *See Tracy, Fairchild, and Webster*, 313
- M
- Maguire, Michael E. *See Vaugulin*, 362; *Erdos*, 379
- Mak, Ivan. *See Poland, Glover, Boatman, Ebetino, and Kende*, 571
- Malaisse, Willy J. *See Couturier, Sener, and Anjaneyulu*, 243
- Malbon, Craig C. The Effects of Thyroid Status on the Modulation of Fat Cell  $\beta$ -Adrenergic Receptor Agonist Affinity by Guanine Nucleotides, 193
- Mantione, Charles R. and Hanin, Israel. Further Characterization of Human Red Blood Cell Membrane Cholinergic Receptors, 28
- Marks, Gerald S. *See Armstrong and Armstrong*, 112; *Neilson and Singer*, 144
- Mason, Ronald P. *See Wolf, Harrelson, Nastainczyk, Philpot, and Kalyanaraman*, 553; *Perez-Reyes*, 594
- Maury, Wendy. *See Davis, Olender, and McDaniel*, 356
- McDaniel, Robert. *See Davis, Olender, and Maury*, 356
- McDermed, John. *See Waggoner and Leighton*, 91
- McLennan, Ian. *See Tomlinson and Mutus*, 33
- McMurchie, E. J. *See Charnock, Gibson, and Raison*, 476
- Meisner, Herman. Binding of Anionic Ligands to Peptic Fragments of Bovine Serum Albumin, 224
- Meisner, Herman, Stair, James, and Neet, Kenneth. Quantitative Assessment of the Competitive Binding of Anionic Ligands to Albumin, 230
- Michell, Robert H. *See Hanley, Lee, and Jones*, 78
- Mico, Bruce A. *See Ortiz de Montellano*, 128; *Ortiz de Montellano and Kunze*, 602
- Miller, Keith W. *See Pang, Braswell, Chang, and Sommer*, 84
- Mitchell, J. R. *See Corcoran, Vaishnav, and Horning*, 536
- Minneman, Kenneth P. *See Weiland and Molinoff*, 341
- Molinoff, Perry B. *See Weiland and Minneman*, 341
- Moore, E. Colleen. *See Preidecker, Agrawal, and Sartorelli*, 507
- Moore, G. J. *See Kwok*, 210
- Morgat, Jean-Louis. *See Kitabgi, Poustis, Granier, Van Rietschoten, Rivier, and Freychet*, 11
- Morishima, Isao, Thompson, W. Joseph, Robison, G. Alan, and Strada, Samuel J. Loss and Restoration of Sensitivity to Epinephrine in Cultured BHK Cells: Effect of Inhibitors of RNA and Protein Synthesis, 370
- Muller-Eberhard, Ursula. *See Liem and Johnson*, 565
- Mutus, Bulent. *See Tomlinson and McLennan*, 33
- Nandi, Dharendra L. and Okita, George T. Effects of Sodium Iodide, Lithium Bromide, and Deoxycholate on Dissociation of [ $^3$ H]-Ouabain- $\text{Na,K-ATPase}$  Complex during Enzyme Isolation, 259
- Nastainczyk, Wolfgang M. *See Wolf, Harrelson, Philpot, Kalyanaraman, and Mason*, 553
- Nathanson, James A.  $\beta$ -Adrenergic-Sensitive Adenylate Cyclase in Choroid Plexus: Properties and Cellular Localization, 199
- Nebert, Daniel W. *See Felton, Ketley, Jakoby, Aitio, and Bend*, 559
- Neet, Kenneth. *See Meisner and Stair*, 230
- Neilson, I. R., Singer, M. A., and Marks, G. S. Association between the Membrane-Fluidizing Properties of Porphyrin-Inducing Activity of Alfaxalone and Related Steroids, 144
- Nemecek, Georgina M., Wells, Jack N., and Butcher, Reginald W. Inhibition of Fibroblast Cyclic AMP Escape and Cyclic Nucleotide Phosphodiesterase Activities by Xanthines, 57
- Nichol, Charles A. *See Duch and Edelstein*, 100
- O
- Okita, George T. *See Nandi*, 259
- Olender, Edward. *See Davis, Maury, and McDaniel*, 356
- Olsson, Ylva. *See Kober and Sjöholm*, 237
- Ortiz de Montellano, Paul R. and Mico, Bruce A. Destruction of Cytochrome P-450 by Ethylene and Other Olefins, 128
- Ortiz de Montellano, Paul R., Kunze, Kent L., and Mico, Bruce A. Destruction of Cytochrome P-450 by Olefins: N-Alkylation of Prosthetic Heme, 602
- Osburn, Bennie I. *See Kawahata, Holmberg, Chuang, and Chuang*, 503
- P
- Palacios, J. M. *See Barbin, Rodergas, Schwartz, and Garbarg*, 1
- Pang, Kam-Yee Y., Braswell, Leon M., Chang, Larry, Sommer, Toby J., and Miller, Keith W. The Perturbation of Lipid Bilayers by General Anesthetics: A Quantitative Test of the Disordered Lipid Hypothesis, 84
- Paterson, Alan R. P., Lau, Eda Y., Dahlig, Ewa, and Cass, Carol E. A Common Basis for Inhibition of Nucleoside Transport by Dipyridamole and Nitrobenzylthioinosine?, 40
- Patton, Suzanne E., Rosen, Gerald M., Rauckman, Elmer J., Graham, Doyle G., Small, Barbara, and Ziegler, Daniel M. Hamster Hepatic Nuclear Mixed-Function Amine Oxidase: Location and Specific Activity, 151
- Patton, Suzanne E., Rosen, Gerald M., and Rauckman, Elmer J. Superoxide Production by Purified Hamster Hepatic Nuclei, 588
- Pavlik, Edward J. and Katzenellenbogen, Benita S. The Stability of the Uterine Estrogen Receptor When Complexed with Estrogens or Antiestrogens, 406
- Perez-Reyes, Edward and Mason, Ronald P. Electron Spin Resonance Study of the Autoxidation of 6-Aminodopamine, 594
- Petrongolo, Carlo. *See Agresti, Buffoni, and Kaufman*, 461
- Philpot, Richard M. *See Wolf, Harrelson, Nastainczyk, Kalyanaraman, and Mason*, 553
- Poirier, M. C., Williams, G. M., and Yuspa, S. H. Effect of Culture Conditions, Cell Type, and Species of Origin on the Distribution of Acetylated and Deacetylated Deoxyguanosine C-8 Adducts of N-Acetoxy-2-acetylaminofluorene, 581
- Poland, Alan, Mak, Ivan, Glover, Edward, Boatman, Rodney, J., Ebetino, Frank H., and Kende, Andrew S. 1,4-Bis [2-(3,5-Dichloropyridyloxy)] benzene, a Potent Phenobarbital-like Inducer of Microsomal Monooxygenase Activity, 571
- Poustis, Claudine. *See Kitabgi, Granier, Van Rietschoten, Rivier, Morgat, and Freychet*, 11
- Preidecker, Paul J., Agrawal, Krishna C., Sartorelli, Alan C., and Moore, E. Colleen. Effects of the Ferrous Chelate of 4-Methyl-5-amino-1-formylisoquinoline Thiosemicarbazone (MAIQ-1) on the Kinetics of Reduction of CDP by Ribonucleotide Reductase of the Novikoff Tumor, 507

## R

- Raess, Beat U. and Vincenzi, Frank F. Calmodulin Activation of Red Blood Cell ( $\text{Ca}^{2+}$  +  $\text{Mg}^{2+}$ )-ATPase and Its Antagonism by Phenothiazines, 253
- Raison, J. K. *See* Charnock, Gibson, and McMurchie, 476
- Rauckman, Elmer J. *See* Patton, Rosen, Graham, Small, and Ziegler, 151; Patton and Rosen, 588
- Redick, Jan A. *See* Taira, Greenspan, Kapke, and Baron, 304
- Reen, S. *See* Brown, Attie, Gardner, Keabian, and Aurbach, 335
- Rice, Jerry M. *See* Wei and Chen, 497
- Rivier, Jean. *See* Kitabgi, Poustis, Granier, Van Rietschoten, Morgat, and Freychet, 11
- Robins, Roland K. *See* Willis and Seegmiller, 287
- Robison, G. Alan. *See* Morishima, Thompson, and Strada, 370
- Rodbell, Martin. *See* Cooper and Londos, 598
- Rodergas, E. *See* Barbin, Palacios, Schwartz, and Garbarg, 1
- Roeske, William R. *See* Yamada and Yamamura, 185
- Roques, Bernard P. *See* Waksman and Changeux, 20
- Rosen, Gerald M. *See* Patton, Rauckman, Graham, Small, and Ziegler, 151; Patton and Rauckman, 558
- Russo, Nino. *See* Barone and Lelj, 331

## S

- Sarraf, Awni M., Tone, Hiroshi, Dandenberg, Peter V., and Heidelberg, Charles. The Incorporation of Trifluorothymidine into Calf Thymus DNA in a Cell-Free System Does Not Lead to Chain Termination, 148
- Sartorelli, Alan C. *See* Preidecker, Agrawal, and Moore, 507
- Sato, Paul H. Synthesis of Ascorbic Acid in Guinea Pigs by an Implanted Dialysis Bag Containing L-Gulonolactone Oxidase, 326
- Scheibel, L. W. and Adler, A. Antimalarial Activity of Selected Aromatic Chelators, 320
- Schelin, Cecilia, Tunek, Andres, Jerström, Bengt, and Jergil, Bengt. Irreversible Binding of Isolated Benzo[a]pyrene Metabolites to Specific Rat Liver Microsomal Proteins, 529
- Schulz, Rudiger, Wüster, Michael, Krenss, Heinz, and Herz, Albert. Lack of Cross-Tolerance on Multiple Opiate Receptors in the Mouse Vas Deferens, 395
- Schwartz, J. C. *See* Barbin, Palacios, Rodergas, and Garbarg, 1
- Seegmiller, J. Edwin. *See* Willis and Robins, 287
- Seglen, Per O. and Gordon, Paul B. Effects of Lysosomotropic Monoamines, Diamines, Amino Alcohols, and Other Amino Compounds on Protein Degradation and Protein Synthesis in Isolated Rat Hepatocytes, 468
- Sener, Abdullah. *See* Couturier, Anjaneyulu, and Malaisse, 243
- Shillady, Donald. *See* Baldwin and Kier, 455
- Shima, Sumio, Kawashima, Yoshiko, Hirai, Masanao, Asakura, Mikio, and Kouyama, Hiroshi. Effects of Androgens on Isopteranol-Sensitive Adenylate Cyclase System of the Rat Prostate, 45
- Siminovitch, Louis. *See* Gupta and Krepinsky, 136
- Singer, M. A. *See* Neilson and Marks, 144
- Sirotnak, Francis M. *See* Chello and Dorick, 274
- Sjöholm, Ingvar. *See* Kober and Olsson, 237; Kober, 421
- Slotkin, Theodore A. *See* Lau, 247
- Small, Barbara. *See* Patton, Rosen, Rauckman, Graham, and Ziegler, 151
- Sommer, Toby J. *See* Pang, Braswell, Chang, and Miller, 84
- Spivak, Charles E. and Albuquerque, E. X. Anatoxin-a: A Novel, Potent Agonist at the Nicotinic Receptor, 384
- Spivak, Charles E. and Taylor, Dermot B. Ion Exchange between Agonist and Inorganic Ions at the Acetylcholine Receptor of *Torpedo californica*, 413
- Stair, James. *See* Meisner and Neet, 230
- Strada, Samuel J. *See* Morishima, Thompson, and Robison, 370

## T

- Taira, Yoshitsugi, Greenspan, Phillip, Kapke, Gordon F., Redick, Jan A., and Baron, Jeffrey. Effects of Phenobarbital, Pregnenolone-16  $\alpha$ -Carbonitrile, and 3-Methylcholanthrene Pretreatments on the Distribution of NADPH-Cytochrome c (P-450) Reductase within the Liver Lobule, 304
- Taylor, Dermot B. *See* Spivak, 413
- Templeton, John F. *See* Kim, LaBella, Zunza, and Zunka, 402
- Thomas, Paul E. *See* Bresnick, Hassuk, Liberator, and Levin, 550
- Thompson, W. Joseph. *See* Morishima, Robison, and Strada, 370
- Thorgeirsson, Snorri S. *See* Wirth, Dybing, and von Bahr, 117
- Tomlinson, George, Mutus, Bulent, and McLennan, Ian. Modulation of Acetylcholinesterase Activity by Peripheral Site Ligands, 33
- Tone, Hiroshi. *See* Sarraf, Danenberg, and Heidelberg, 148
- Tracy, James W., Fairchild, Edward H., Lucas, Samuel V., and Webster, Leslie T. Jr., Isolation, Characterization, and Synthesis of an Immunoregulatory Metabolite of Nidazole: 1-Thiocarbomoyl-2-imidazolidinone, 313
- Triggle, David J. *See* Tsai, Albuquerque, Aronstam, Eldefrawi, and Eldefrawi, 159; Aronstam, Eldefrawi, Eldefrawi, Albuquerque, and Jim, 179
- Tsai, Ming-Chen, Albuquerque, Edson X., Aronstam, Robert S., Eldefrawi, Amira T., Eldefrawi, Mohyee E., and Triggle, David J., Sites of Action of Phencyclidine. I. Effects on the Electrical Excitability and Chemosensitive Properties of the Neuromuscular Junction of Skeletal Muscle, 159; *See also* Albuquerque, Aronstam, Eldefrawi, and Eldefrawi, 167
- Tunek, Andres. *See* Schelin, Jerström, and Jergil, 529

## V

- Vaishnav, Y. N. *See* Corcoran, Mitchell, and Horning, 536
- Van Rietschoten, Jurphaas. *See* Kitabgi, Poustis, Granier, Rivier, Morgat, and Freychet, 11
- Vauguelin, Georges and Maguire, Michael E. Inactivation of  $\beta$ -Adrenergic Receptors by N-Ethylmaleimide in S49 Lymphoma Cells. Agonist Induction of Functional Receptor Heterogeneity, 362
- Vincenzi, Frank F. *See* Raess, 253
- von Bahr, Christer. *See* Wirth, Dybing, and Thorgeirsson, 117

## W

- Waggoner, W. G., McDermid, John, and Leighton, H. J. Presynaptic Regulation of Tyrosine Hydroxylase Activity in Rat Striatal Synaptosomes by Dopamine Analogs, 91
- Waksman, Gilles, Changeux, Jean-Pierre, and Roques, Bernard P. Structural Requirements for Agonist and Noncompetitive Blocking Action of Acylcholine Derivatives on *Electrophorus electricus* Electropaque 20
- Webster, Leslie T. Jr., *See* Tracy, Fairchild, and Lucas, 313
- Wei, Shu-Jing, C., Chen, Beatrice P., and Rice, Jerry M. Comparative Effects of Methyl- and Ethylnitrosourea on DNA Directing Cell-Free DNA-Dependent Synthesis of  $\beta$ -Galactosidase, 497
- Weiland, Gregory A., Minneman, Kenneth P., and Molinoff, Perry B. Thermodynamics of Agonist and Antagonist Interactions with Mammalian  $\beta$ -Adrenergic Receptors, 341
- Wells, Jack N. *See* Nemecek and Butcher, 57
- Wicks, Wesley D. *See* Koontz, 65
- Williams, G. M. *See* Poirier and Yuspa, 581
- Willis, Randall C., Robins, Roland K., and Seegmiller, J. Edwin. An *in Vivo* and *in Vitro* Evaluation of 1- $\beta$ -D-Ribofuranosyl-1,2,4-triazole-3-carboxamide: An Inhibitor of Human Lymphoblast Purine Nucleoside Phosphorylase, 287
- Wirth, Peter J., Eybing, Erik, von Bahr, Christer, and Thorgeirsson, Snorri S. Mechanism of N-Hydroxylacetylarylamine Mu-

tagenicity in the *Salmonella* Test System: Metabolic Activation of *N*-Hydroxyphenacetin by Liver and Kidney Fractions from Rat, Mouse, Hamster, and Man, 117

**Wolf, C. Roland, Harrelson, Willard G., Jr., Nastainczyk, Wolfgang M., Philpot, Richard M., Kalyanaraman, B., and Mason, Ronald P.** Metabolism of Carbon Tetrachloride in Hepatic Microsomes and Reconstituted Monooxygenase Systems and Its Relationship to Lipid Peroxidation, 553

**Woynarowski, Jan M. and Beerman, Terry A.** Inhibition of DNA Replication of HeLa S<sub>3</sub> Cells by Macromomycin-I, an Antitumor Protein Antibiotic, 491

**Wüster, Michael.** See *Schulz, Krenss, and Herz*, 395

## Y

**Yamada, Shizuo, Yamamura, I., and Roeske, William R.** Alterations in Cardiac Autonomic Receptors following 6-Hydroxydopamine Treatment in Rats, 185

**Yamamura, Henry I.** See *Yamada, and Roeske*, 185

**Yuspa, R. H.** See *Poirier and Williams*, 581

## Z

**Ziegler, Daniel M.** See *Patton, Rosen, Rauckman, Graham, and Small*, 151

**Zunka, Federika.** See *Kim, LaBella, Zunza, and Templeton*, 402

**Zunza, Hilda.** See *Kim, LaBella, Zunka, and Templeton*, 402

CUMULATIVE SUBJECT INDEX<sup>1</sup> FOR VOLUMES 17 AND 18

## A

- Acetamide**  
metabolite, from reduction of metronidazole by xanthine oxidase, 18, 105
- Acetaminophen**  
adduct formation, inhibition by ascorbate, 18, 536  
arylate intermediate from, 18, 536  
covalent binding, inhibition by ascorbate, 18, 536
- N*-Acetoxy-2-acetylaminofluorene**  
in DNA adducts (cultured cells), 18, 581
- N*-( $\beta$ -Acetoxyethyl)pyridinium**  
ion, conformational analysis: comparisons with acetylcholine, 18, 331
- 2-Acetylaminofluorene-DNA**  
binding, inhibition by paraoxon cell culture), 18, 581
- N*-Acetylarylamines**  
mutagenicity, mechanism (bacteria), 18, 117
- N*-Acetylation**  
arylamines drugs, 17, 367
- N*-Acetyl-*p*-benzoquinoneimine**  
from both acetaminophen and *N*-hydroxyacetaminophen, 18, 536
- Acetylcholine**  
comparison with conformational analysis of *N*-( $\beta$ -acetoxyethyl)-pyridinium ion, 18, 331  
derivatives, agonist and blocking properties on electroplaque (electric eel), 18, 20  
release, effects of  $\Delta^9$ -tetrahydrocannabinol (frog), 17, 344
- Acetylcholine receptor**  
blockade by nereistoxin, 17, 127  
electric ray electric organ membranes, 17, 127, 283; 18, 167  
ion exchange between agonists and inorganic ions at, 18, 413  
ionic channel, 17, 283; 18, 167; complex, 18, 384  
nicotinic  
electric ray electropax tissue, 18, 413  
rat brain, 17, 149
- Acetylcholinesterase**  
activity, modulation by peripheral site ligands (electric eel), 18, 33  
inhibition by phenacyclidine, 18, 159
- N*-Acetyltransferases**  
immunochemical studies (rabbit), 17, 367
- $\alpha_1$ -Acid glycoprotein**  
propranolol binding (human), 17, 187
- Actinomycin D**  
effect on response of BHK cells to epinephrine, 18, 370  
and spin-labeled derivatives, superoxide formation, 17, 432
- Action potential**  
prolongation by phencyclidine, 18, 159
- Activator protein, see Protein**
- Actodigin**  
crystal structure, 17, 43  
inhibition of  $\text{Na}^+, \text{K}^+$ -adenosinetriphosphatase, 17, 43
- Actodigin genin**  
inhibition of  $\text{Na}^+, \text{K}^+$ -adenosinetriphosphatase, 17, 43
- Acylocholine**  
analogs, agonist and blocking properties on electroplaque (electric eel), 18, 20
- Adenosine**  
analogs  
inhibition of adenylate cyclase (rat), 18, 598  
puromycin aminonucleoside, 17, 262  
-induced alterations in adenosine 3',5'-monophosphate levels in epidermal strips, effects of psoriasis (human), 18, 49  
inhibition of methylation of nuclear RNA, mechanism (cell culture), 18, 483
- Adenosine kinase**  
deficiency, human lymphoblast line, 18, 287
- Adenosine 3',5'-monophosphate**  
accumulation,  $\beta$ -adrenergic receptor-regulated: desensitization (lymphoma cells), 18, 379  
escape from fibroblasts, inhibition by xanthines (cell culture), 18, 57  
formation, prostate: effects of androgens (rat), 18, 45  
generation, linked to  $\beta$ -adrenergic receptors, 17, 8  
levels in  
diaphragm (rat), 17, 73  
epidermal strips, adenosine-induced alterations (human, mouse), 18, 49
- rat**  
heart: cells, 17, 8; left atrium, 17, 180  
lung cells, 17, 8  
relation to secretion in parathyroid cells (bovine), 18, 335
- Adenosinetriphosphatase**  
activity, myocardium: relationship to membrane fluidity during hibernation (ground squirrel), 18, 476  
chicken gizzard smooth muscle, 17, 66  
inhibition by modulator interacting agents, 17, 66
- Adenosinetriphosphatase ( $\text{Ca}^{2+} + \text{Mg}^{2+}$ )**  
human erythrocyte membranes, 18, 253  
phenothiazine inhibition, 18, 253
- Adenosinetriphosphatase ( $\text{Na}^+ + \text{K}^+$ )**  
dog kidney, 18, 53  
rat brain, 17, 43  
subunit crosslinking, effects of ouabain, 18, 53
- Adenosinetriphosphatase ( $\text{Na}^+ + \text{K}^+$ )-[ $^3\text{H}$ ]ouabain**  
complex, dissociation during enzyme isolation, heart (rabbit), 18, 259
- Adenosine triphosphate**  
cellular pools, labeling with  $^{32}\text{P}$  (glioma cells), 18, 427
- S*-Adenosylhomocysteine**  
inhibition of methylation of nuclear RNA (cell culture), 18, 483
- S*-Adenosylhomocysteine hydrolase**  
in adenosine inhibition of methylation of nuclear RNA (cell culture), 18, 483
- S*-Adenosyl-L-methionine**  
in adenosine inhibition of methylation of nuclear RNA (cell culture), 18, 483  
nuclear ribosomal RNA and poly(A) RNA synthesis, effect of 5-azacytidine and dihydro-5-azacytidine (leukemia cells), 17, 111
- Adenylate cyclase**  
activation, and high and low affinity states of  $\beta$ -adrenergic receptor, 17, 14  
adenosine receptor-mediated inhibition by GTP-dependent process, 18, 598  
 $\beta$ -adrenergic sensitive, choroid plexus (cat), 18, 199  
cat heart ventricular membranes, 17, 328  
desensitization, 18, 379  
frog erythrocytes, 18, 348  
interaction with  $\beta$ -adrenergic receptors, 18, 362  
and internalization of  $\beta$ -adrenergic receptor recognition sites, 18, 348
- rat**  
cerebral cortex, 18, 598  
heart, 17, 180  
pancreas plasma membranes, 17, 268  
prostate, 18, 45  
responsiveness

<sup>1</sup> Boldface numbers indicate appropriate volume; lightface numbers indicate pagination.

- to catecholamines (BHK cells), 18, 370
- effect of hypothyroidism, 17, 180
- S49 lymphoma cells, 18, 362, 379
- system, isoproterenol sensitive: effects of androgens, 18, 45
- turkey erythrocytes, 17, 163
- Adenylyl cyclase, *see* Adenylate cyclase
- Adipocyte, *see* Fat cells
- Adrenal
  - medulla, localization of semidehydroascorbate reductase (bovine), 17, 421
- $\beta$ -Adrenergic drugs
  - crystallographic and theoretical results: PCILO method, 17, 339
  - key features, 17, 339
- $\alpha$ -Adrenergic receptor
  - desensitization, 18, 356
  - rat parotid acinar cells, 18, 356
- $\alpha_1$ -Adrenergic receptor
  - effect on
    - glycogen synthase activity in hypothyroidism (rat), 18, 72
    - phosphatidylinositol labeling in hypothyroidism (rat), 18, 72
- $\beta$ -Adrenergic receptor
  - agonist-induced transconformation, 17, 163
  - binding, prostate: effects of androgens (rat), 18, 45
  - cat heart: right and left atria and papillary muscles, 17, 328
  - effects of agonist interaction (BHK cells), 18, 370
  - frog erythrocytes, 18, 348
  - inactivation by *N*-ethylmaleimide, 18, 362
  - internalization during receptor desensitization, 18, 348
  - iodohydroxybenzylpindolol binding, 18, 341
  - quantitative analysis, 17, 14
  - rat
    - cerebral cortex, cerebellum, heart, and lung, 18, 341
    - fat cell membranes, 18, 193
    - regulated magnesium transport and cyclic AMP accumulation, independent desensitization of, 18, 379
    - S49 lymphoma cells, 18, 362, 379
    - turkey erythrocyte, 17, 1; membranes, 17, 163
- $\beta_1$  and  $\beta_2$  Adrenergic receptors
  - criteria for classification, 17, 8
  - mammal tissues, 17, 1
  - rat heart and lung cells, 17, 8
- $\beta_2$ -Adrenergic receptors
  - adenylate cyclase, choroid plexus (cat), 18, 199
- Adrenoceptor, *see* Adrenergic receptor
- Affinity labeling
  - angiotensin II receptors, with photolabile antagonist, 18, 210
- Affinity states
  - $\beta$ -adrenergic receptor, resolution by computer modeling, 17, 14
- Aflatoxin
  - B<sub>1</sub> and B<sub>2</sub> metabolism: genetic expression (mouse, inbred strains), 18, 296
- Agonist
  - acyl analogs of acetylcholine action as, structural requirements, 18, 20
  - binding, entropy and enthalpy decreases of, 18, 341
  - induction of functional receptor heterogeneity, 18, 362
  - and inorganic ion exchange at acetylcholine receptor, 18, 413
  - partial
    - iodohydroxybenzylpindolol, cardiac tissues (cat), 17, 328
    - nereistoxin, acetylcholine receptor, 17, 172
- Albumin
  - ligand binding to, Scatchard analysis (bovine), 18, 230
  - serum
    - binding sites for nonsteroidal anti-inflammatory drugs, 18, 421
    - drug binding, interaction between phenytoin and valproate (human), 18, 237
    - peptic fragments, anionic ligand binding (bovine), 18, 224
    - propranolol binding (human), 17, 187
    - specificity of drug binding sites (human), 18, 157
- Alfaxalone
  - association between membrane-fluidizing properties and porphyrin-inducing activity, embryo liver cells (chicken), 18, 144
- Algae
  - blue-green, *Anabaena flosaquae*: anatoxin-a from, 18, 384
- Alkaline phosphatase
  - activity, vascular smooth muscle plasma membrane: effect of hypertension (rat), 17, 137
- Amines
  - lysosomotropic, effects on protein degradation and synthesis in hepatocytes (rat), 18, 468
- Amino acids
  - from protein degradation, 18, 468
- 8-Aminoadenosine 3',5'-monophosphate
  - cytotoxic effects in cultured hepatoma cells (rat), 18, 65
- $\gamma$ -Aminobutyric acid receptor
  - binding, in cultured brain cells (mouse), 17, 285
- 6-Aminodopamine
  - autoxidation, 18, 594
- $\delta$ -Aminolevulinic acid
  - incorporation into cytochrome *P*-450 heme (rat), 17, 395
- Amylase
  - secretion, pancreas fragments: effect of guanyl nucleotides (rat), 17, 268
- Anatoxin-a
  - nicotinic agonist, 18, 384
- Androgen
  - and castration, effects on isoproterenol-sensitive adenylate cyclase system of prostate (rat), 18, 45
- Androgen receptor
  - inhibition by metal ions, 17, 156
  - mouse prostate gland, 17, 156
- Anesthetics
  - general
    - disordered lipid hypothesis of, 18, 84
    - perturbation of lipid bilayers by, 18, 84
- Angiotensin II receptors
  - photoaffinity labeling, 18, 210
  - rat uterus, 18, 210
- Antagonist
  - binding, entropy increases of, 18, 341
  - folate, effect on histamine metabolism, 18, 100
- Anthracycline
  - antibiotics, interactions with xanthine oxidase (bovine), 17, 95
  - free radicals, formation (bovine), 17, 95
  - interaction with covalently closed circular DNA (phage), 17, 100
  - mechanism of action, 17, 100
- Antiandrogen
  - effects on nuclear kinases (rat), 17, 212
- Antibiotic
  - antitumor protein, macromycin-I: inhibition of DNA replication (HeLa cells), 18, 491
- Anticancer
  - folate antagonists, effect on histamine metabolism, 18, 100
- Anticonvulsants
  - in metaphase arrest and microtubular polymerization, 17, 275
- Antiestrogens
  - interaction with estrogen receptor, 18, 406
- Antifolates
  - alteration of histamine metabolism, 18, 100
  - diaminopyrimidine, lipophilic: biochemical pharmacology *in vitro* (human, mouse), 18, 521
- Anti-inflammatory drugs
  - nonsteroidal, binding sites on serum albumin (human), 18, 421
- Antimalarial
  - activity, aromatic chelators, 18, 320
- Antirheumatic drugs
  - binding sites on serum albumin (human), 18, 421
- Antitumor

- drugs, DNA damage after treatment with (virus), 17, 388  
 protein antibiotic, macromycin-I: inhibition of DNA replication (HeLa cells), 18, 491
- Aorta**  
 strips: norepinephrine uptake, effect of phthalane and thiophthalane inhibitors (rabbit), 17, 321
- AR-L 57, *see* 6-(2,4-Dimethoxyphenyl)-imidazo-(4,5- $\beta$ )-pyridine
- Aromatic chelators**  
 antimalarial activity, 18, 320
- Artery**  
 mesenteric, smooth muscle plasma membrane: effect of hypertension on biochemistry (rat), 17, 137
- Aryl hydrocarbon hydroxylase, *see* Benzopyrene 3-monooxygenase
- 5-Aryltetrahydro- $\gamma$ -carboline  
 neuroleptic activity, conformational requirements for (rat), 17, 38
- Ascorbic acid**  
 inhibition of mutagenicity, *N*-hydroxyphenacetin and *p*-nitrosophenetole (bacteria), 18, 117  
 synthesis *in vivo*, by implanted dialysis bag containing L-gulonolactone oxidase (guinea pig), 18, 326
- Atrium**  
 adenylate cyclase system, effect of hypothyroidism (rat), 17, 180
- Autonomic receptors**  
 heart, alterations after 6-hydroxydopamine (rat), 18, 185
- Autoxidation**  
 6-aminodopamine, 18, 594
- Axon**  
 sodium pump, inhibition by AR-L 57 (squid), 17, 350
- Axoplasm**  
 transport, fast: inhibition by delayed neurotoxic organophosphorus esters (rat), 17, 56
- AY-22,241, *see* Actodigin
- 5-Azacytidine  
 effects on nuclear RNA (leukemia cells), 17, 250
- Azapropazone**  
 binding sites on serum albumin (human), 18, 421
- B**
- Bacteria**  
*Escherichia coli*: RNA polymerase, effect of 6-mercaptapurine ribonucleotides, 18, 503  
*Salmonella typhimurium*, mutagenicity of *N*-hydroxyacetylarylamine, 18, 117
- Bacteriophage**  
 PM-2, covalently closed circular DNA, 17, 100
- Benzo[a]pyrene**  
 metabolism (rabbit), 17, 225  
 metabolites, binding to liver microsome proteins (rat), 18, 529
- Benzopyrene 3-monooxygenase**  
 in glutathione transferase not associated with *Ah* locus (mouse), 18, 559
- Benzo[a]pyrene 4,5-oxide**  
 substrate for liver glutathione transferase (mouse), 18, 559
- BHK cells, *see* Fibroblasts; Kidney
- Bicyclic inhibitors**  
 of norepinephrine uptake, 17, 321
- Binding**  
 anionic ligands to serum albumin fragments (bovine), 18, 224  
 competitive, anionic ligands to albumin, 18, 230  
 drugs, to serum albumin: interaction between phenytoin and valproate (human), 18, 237  
 irreversible, benzo[a]pyrene metabolites to liver microsome proteins (rat), 18, 529  
 neurotensin  
   to brain synaptic membranes (rat), 18, 11  
   to colon carcinoma cell line (HT 29) (human), 18, 11  
   to extraneural and neural receptors (human, rat), 18, 11  
 opiate, phosphatidylserine and (rat), 17, 290  
 sites, high affinity: [ $^3$ H]histamine in brain (rat), 18, 1  
 specific, to  $\beta$ -adrenergic receptors in heart and lung (rat), 17, 8
- Binding constants**  
 and antimalarial activity of aromatic chelators, 18, 320
- Bioassay**  
*in vitro*, intestinal smooth muscle (guinea pig), 18, 11
- 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene  
 induction of monooxygenase activity in microsomes (mouse), 18, 571
- Bleomycin**  
 DNA damage after treatment with (virus), 17, 388
- Blood**  
 platelets: serotonin secretion, effect of extracellular pH (rat), 17, 356
- Blood vessels**  
 helical strips, dorsal pedal arteries and medial saphenous veins: effects of nitroglycerin (dog), 18, 112
- Bone**  
 calcium mobilization, effect of 1,24(R),25-trihydroxycholecalciferol (rat), 17, 362
- Brain**  
 $\alpha$ -bungarotoxin receptor (rat), 17, 149  
 cells, cultured:  $\gamma$ -aminobutyric acid receptor binding (mouse), 17, 285  
 cerebrum, cortex  
   adenylate cyclase: adenosine receptor-mediated inhibition by GTP-dependent process, 18, 598  
   cyclic nucleotide phosphodiesterase activation by gangliosides (rat), 17, 206  
 dopamine receptors, conformational requirements for interaction with (rat), 17, 38  
 high-affinity binding sites of [ $^3$ H]histamine (rat), 18, 1  
 lipid bilayers, chronic ethanol effect (mouse), 17, 52  
 membranes, physical state: effect on phosphatidylserine requirement for opiate binding (rat), 17, 290  
 mitochondria  
   lipid-protein interactions in monoamine oxidase *in situ* (rat), 17, 192  
   monoamine oxidases A and B (rat), 18, 267  
 monooxygenase activities, heme-mediated stimulation (rabbit), 17, 225  
 nicotinic receptor, affinity reagents for (rat), 17, 149  
 striatum  
   muscarinic receptor, [ $^3$ H]quinuclidinyl benzilate binding (rat), 17, 24  
   synaptosomes: presynaptic regulation of tyrosine hydroxylase activity by dopamine analogs (rat), 18, 91  
 synaptic membranes, neurotensin binding (rat), 18, 11
- Bretylium**  
 effects on chromaffin granule function, 18, 606
- Bromoacetylcholine**  
 receptor alkylation with (rat), 17, 149
- $\alpha$ -Bungarotoxin**  
 binding  
   to acetylcholine receptors, inhibition by nereistoxin (electric ray), 17, 172  
   inhibition, 18, 159  
 receptor (acetylcholine) saturation, 18, 413
- $\alpha$ -Bungarotoxin receptor**  
 rat brain, 17, 149
- C**
- Calcium**  
 accumulation, vascular smooth muscle plasma membrane: effect of hypertension (rat), 17, 137  
 -binding protein synthesis, effect of 1,24(R),25-trihydroxycholecalciferol (rat), 17, 362
- Ca $^{2+}$**   
 peripheral site ligand activation of acetylcholinesterase activity (electric eel), 18, 33  
 -regulated modulator protein interacting agents (chicken), 17, 66  
 -stimulated protein kinase and ATPase (chicken), 17, 66



- dependent activator protein, 17, 206
- effect on opiate binding to brain membranes (rat), 17, 290
- fluxes in sarcoplasmic reticulum vesicles, effect of dibucaine (rabbit), 17, 61
- in histamine-induced glycogenolysis in brain (mouse), 17, 301
- homeostasis, alteration by taurine (rat), 17, 295
- mobilization, bone: effect of 1,24(R),25-trihydroxycholecalciferol (rat), 17, 362
- potassium release mediated by, 18, 356
- uptake, islet cells: effect of quinine and ionophores (rat), 18, 243
- Calmodulin**
  - activation of erythrocyte ( $\text{Ca}^{2+} + \text{Mg}^{2+}$ )-adenosinetriphosphatase, 18, 253
  - interacting agents, myosin phosphorylation inhibition (chicken), 17, 66
- Calorimetry**
  - differential scanning, myocardial membranes (ground squirrel), 18, 476
- Carbon tetrachloride**
  - initiated lipid peroxidation (rat), 17, 408
  - metabolism, liver microsomes and reconstituted monooxygenase systems: relationship to lipid peroxidation (rabbit, rat), 18, 553
- Carcinogen**
  - N*-hydroxy-2-acetylaminofluorene, activation by cumene hydroperoxide-hematin, 17, 233
- Carcinogen-DNA**
  - adducts, radioimmunoassay, 18, 581
- Carcinoma**
  - colon, cell line (H 29): neurotensin binding (human), 18, 11
- Cardiac glycosides**
  - radioreceptor assay, and progesterone derivatives, 18, 402
- Cardioactive drug**
  - AR-L 57 [6-(2,4-dimethoxyphenyl)-imidazo-(4,5- $\beta$ )-pyridine], inhibition of sodium pump in axons (squid), 17, 350
- Carrier**
  - allosteric, for transport: serotonin, low concentrations, 18, 447
  - sites, specific: pinealocyte membranes (bovine), 18, 438
- Catecholamine**
  - secretion, effects of *N,N*-diisopropyl-*N'*-isoamyl-*N'*-diethylaminoethylurea (*P*-286), 18, 606
  - tachyphylaxis to (BHK cells), 18, 370
- Cell**
  - free system, trifluorothymidine incorporation into thymus DNA: no chain termination (bovine), 18, 148
- Central nervous system**
  - muscarinic sites, effect of temperature (frog), 17, 141
- Cerebrospinal fluid**
  - choroid plexus, receptors (cat), 18, 199
- Cerebrum, see Brain**
- Chemotherapy**
  - carrier-bound methotrexate, interaction with L1210 cells (mouse), 17, 382
- Chloramphenicol**
  - inactivation of cytochrome *P*-450 (rat), 17, 427
- Chlorinated aromatic hydrocarbon**
  - toxicity, and Ah locus (mouse), 17, 86
- Chlormadinone acetate**
  - and digitalis receptor binding, 18, 402
- 1-Chloro-2,4-dinitrobenzene**
  - substrate for liver glutathione transferase (mouse), 18, 559
- Cholinergic receptor**
  - human erythrocyte membrane, 18, 28
  - muscarinic, desensitization, 18, 356
  - rat parotid acinar cells, 18, 356
- Cholinesterase**
  - inhibition with diisopropylfluorophosphate (rat), 17, 24
- Choroid plexus**
  - $\beta$ -adrenergic-sensitive adenylate cyclase, properties and cellular localization (cat), 18, 199
- Chromaffin**
  - cells, cultured: secretion from (bovine), 18, 606
  - granules
    - function, chemiosmotic mechanisms: effects of bretylium, guanethidine and *N,N*-diisopropyl-*N'*-isoamyl-*N'*-diethylaminoethylurea (*P*-286), 18, 606
    - membrane,  $\text{H}^+$  electrochemical gradient across, 18, 606
- Cleavage**
  - reductive glycosidic, anthracycline antibiotics, 17, 95
- Computer**
  - modeling, ligand binding to  $\beta$ -adrenergic receptor, 17, 14
  - PROPHET studies, digitalis analogs, 17, 43
- Conformation**
  - analysis, PCILO method: *N*-( $\beta$ -acetoxyethyl)pyridinium ion, comparisons with acetylcholine, 18, 331
  - behavior by NMR, acetylcholine analogs, 18, 20
  - change, agonist induced, 18, 362
  - requirements for interaction with central dopamine receptor, 17, 38
  - tertiary and quaternary, ( $\text{Na}^+ + \text{K}^+$ )-activated adenosinetriphosphatase: ouabain-induced changes, 18, 53
- Cordycepin**
  - and methylation of nuclear RNA (cell culture), 18, 483
- Crosslinking**
  - adenosinetriphosphatase ( $\text{Na}^+ + \text{K}^+$ ), effects of ouabain, 18, 53
- Cross-tolerance**
  - lack of, on multiple opiate receptors in vas deferens (mouse), 18, 395
- Cryptopleurine**
  - cross-resistance studies, 18, 136
- Crystallography**
  - $\beta$ -adrenergic drugs, 17, 339
- Cumene hydroperoxide-hematin**
  - activation of *N*-hydroxy-2-acetylaminofluorene, 17, 233
- Cumene hydroperoxyl radical**
  - spin trapping, 17, 233
- Currents**
  - end-plate, *see* End-plate
  - time- and voltage-dependent: effects of piperocaine on ion channel of acetylcholine receptor (electric ray), 17, 283
- Cyanofenphos**
  - effect on fast axoplasmic transport (rat), 17, 56
- Cyclic AMP, *see* Adenosine 3',5'-monophosphate**
- Cyclic GMP, *see* Guanosine 3',5'-monophosphate**
- Cyclic nucleotide**
  - derivatives, cytotoxic effects in hepatoma cells (rat), 18, 65
- Cyclic nucleotide phosphodiesterase**
  - activation by gangliosides, 17, 206
  - activity, fibroblast: inhibition by xanthines (cell culture), 18, 57
  - rat
    - cerebral cortex, 17, 206
    - diaphragm, 17, 73
- Cycloheximide**
  - effect on response of BHK cells to epinephrine, 18, 370
- Cyproterone acetate**
  - effects on nuclear protein phosphokinases and phosphatases of ventral prostate (rat), 17, 212
- Cytidine 5'-diphosphate**
  - reduction by ribonucleotide reductase, kinetics, 18, 507
- Cytochrome *P*-450**
  - dependent monooxygenase system, carbon tetrachloride metabolism in (rabbit), 18, 553
  - destruction by olefins, 18, 602
  - development, neonatal imprinting and (rat), 18, 543
  - interaction with epoxides, 18, 128
  - liver
    - heme turnover (rat), 17, 395
    - inactivation by chloramphenicol (rat), 17, 427
    - microsomes, destruction by olefins (rat), 18, 128
    - microsomes, kidney and lung: induction by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (rabbit), 18, 565

- nucleolus, liver: location (rat), 18, 550  
 nucleus, liver (hamster), 18, 151  
 transplacental induction (rabbit), 17, 218  
 two forms in lung microsomes quantitation by substrate specificity (rabbit), 17, 415
- Cytosol  
 prostate gland, inhibition of androgen receptors by divalent metal ions (mouse), 17, 156
- Cytotoxicity  
 methotrexate (hepatoma cells), 17, 105  
 8-substituted cyclic nucleotide derivatives, in hepatoma cells (rat), 18, 65
- D**
- Decamethonium  
 receptor saturation, 18, 413
- 2'-Deoxyadenosine  
 and methylation of nuclear RNA (cell culture), 18, 483
- 3'-Deoxyadenosine, *see* Cordycepin
- Deoxycholate  
 dissociation of [<sup>3</sup>H]ouabain-Na,K-adenosinetriphosphatase complex, 18, 259
- Deoxyguanosine C-8  
 acetylated and deacetylated, adducts of *N*-acetoxy-2-acetylaminofluorene, 18, 581
- Deoxyuridine triphosphate nucleotidohydrolase  
 role in 5-fluorodeoxyuridine metabolism in tumor cells (human), 18, 513
- Deoxyuridylate  
 pool size, effects of methotrexate and thymidine (cell culture), 18, 281
- Dependence  
 lack of, multiple opiate receptors in vas deferens (mouse), 18, 395
- Desbromoleptophos  
 effect on fast axoplasmic transport (rat), 17, 56
- Desensitization  
 $\beta$ -adrenergic receptor, 18, 348  
 effect on antagonism of histamine response by phenoxybenzamine (guinea pig), 17, 309  
 independent,  $\beta$ -adrenergic receptor-regulated events, 18, 379
- Desipramine  
 inhibition of norepinephrine uptake, comparison with bicyclic inhibitors, 17, 321
- Diaminopyrimidine antifolates  
 lipophilic, biochemical pharmacology *in vitro* (human, mouse), 18, 521
- Diaphragm  
 contraction, enhancement by xanthines (rat), 17, 73  
 phosphodiesterase from (rat), 17, 73
- Dibucaine  
 effect on calcium fluxes (rabbit), 17, 61
- Dibutyl cyclic GMP  
 interaction with pancreozymin (rat), 17, 268
- Digitalis  
 analogs, structure-activity studies, 17, 43
- Digitalis receptor  
 binding by progesterone derivatives, 18, 402  
 dog heart, 18, 402
- Digitoxigenin glucoside  
 inhibition of Na<sup>+</sup>,K<sup>+</sup>-adenosinetriphosphatase, 17, 43
- Dihydro-5-azacytidine  
 effects on nuclear RNA (leukemia cells), 17, 250
- Dihydrofolate  
 pool size, effects of methotrexate and thymidine (cell culture), 18, 281
- Dihydrofolate reductase  
 effect of lipophilic diaminopyrimidine antifolates *in vitro* (human, mouse), 18, 521
- K<sub>i</sub>* values, for lipophilic diaminopyrimidine antifolates *in vitro* (human, mouse), 18, 521  
 target enzyme, methotrexate (hepatoma cells), 17, 105
- 1,25-Dihydroxycholecalciferol  
 comparison with 24(R),25-dihydroxycholecalciferol (rat), 17, 362
- 24(R),25-Dihydroxycholecalciferol  
 comparison with 1,25-dihydroxycholecalciferol (rat), 17, 362
- Diisopropylfluorophosphate  
 cholinesterase inhibition (rat), 17, 24
- N,N*-Diisopropyl-*N'*-isoamyl-*N'*-diethylaminoethylurea (*P*-286)  
 effects on chromaffin granule function 18, 606
- 6-(2,4-Dimethoxyphenyl)-imidazo-(4,5- $\beta$ )-pyridine  
 inhibition of sodium pump in axons (squid), 17, 350
- 7,12-Dimethylbenz[*a*]anthracene  
 metabolism (rabbit), 17, 225
- Dinitrate  
 absence of formation during nitroglycerin-induced relaxation of blood vessels (dog), 18, 112
- 2,3-Dinitrofluorobenzene  
 delayed hypersensitivity, suppression by 1-thiocarbamoyl-2-imidazolidinone (mouse), 18, 313
- Diphenylhydantoin, *see* Phenytoin
- Dipyridamole  
 inhibition of nitrobenzylthioinosine binding and uridine transport, 18, 40
- DNA  
 covalently closed circular, interaction with anthracyclines (phage), 17, 100  
 damage, from antitumor drugs (virus), 17, 388  
 -dependent RNA polymerase, effect of 6-mercaptapurine ribonucleotides, 18, 503  
 -directed cell-free synthesis of  $\beta$ -galactosidase, 18, 497  
 repair, effect of macromycin-I (HeLa cells), 18, 491  
 replication, inhibition by macromycin-I (HeLa cells), 18, 491  
 thymus, incorporation of trifluorothymidine in a cell-free system: no chain termination (bovine), 18, 148
- DNA glycosylase  
 5-fluorouracil-containing DNA, tumor cells (human), 18, 513
- DNA polymerase- $\alpha$   
 5-fluorodeoxyuridine triphosphate and deoxyuridine triphosphate incorporation, tumor cells (human), 18, 513  
 inhibition by deoxyribonucleoside triphosphates (bovine), 17, 256  
 regulation (bovine), 17, 256  
 role in 5-fluorodeoxyuridine metabolism in tumor cells (human), 18, 513
- Dopamine  
 agonists, inhibition of tyrosine hydroxylase activity in striatal synaptosomes (rat), 18, 91  
 antagonists, conformational requirements for activity, 17, 38  
 enzymic conversion to norepinephrine, production of semidehydroascorbate, 17, 421
- Dopamine  $\beta$ -hydroxylase, *see* Dopamine  $\beta$ -monooxygenase
- Dopamine  $\beta$ -monooxygenase  
 coupling of semidehydroascorbate reductase to, 17, 421
- Dopamine receptor  
 bovine parathyroid cell, 18, 335  
 plasma membrane, presynaptic: regulation of tyrosine hydroxylase activity, 18, 91  
 rat striatum, 18, 91
- Dose-response  
 curve to histamine produced by phenoxybenzamine (guinea pig), 17, 309
- Drug  
 binding to  
 albumin fragments, 18, 224  
 serum albumin (human), 18, 157, 237, 421  
 inhibition of iodohydroxybenzylpindolol binding (rat), 18, 341  
 interacting, modulator: myosin phosphorylation inhibition (chicken), 17, 66

## E

## Electric eel

*Electrophorus electricus*

- acetylcholinesterase from, modulation of activity by peripheral site ligands, 18, 33
- electroplaque, pharmacological properties of acyl analogs of acetylcholine, 18, 20

Electric organ, *see* Electric ray

## Electric potential

- eseroline and morphine, 18, 461

## Electric ray

- Torpedo californica*: electroplax, ion exchange at acetylcholine receptor, 18, 413

*Torpedo ocellata*, electric organ

- effect of piperocaine, 17, 283
- membranes, effect of phencyclidine, 18, 159
- membranes, nereistoxin interaction with acetylcholine receptor, 17, 172
- receptors, effect of phencyclidine, 18, 167

## Electron paramagnetic resonance

- autooxidation of 6-aminodopamine, 18, 594
- lipid-protein interactions in monoamine oxidase, 17, 192
- total lipid extract from myocardial membranes (ground squirrel), 18, 476

Electron spin resonance, *see* Electron paramagnetic resonance

## Electrophoresis

- gel, two-dimensional: phosphoproteins (glioma cells), 18, 427
- polyacrylamide gel, monoamine oxidases A and B (human, rat), 17, 199

Electroplaque, *see* Electric eelElectrostatic potential, *see* Electric potential

## Electrovalence

- changes of acetylcholine receptor, 18, 413

## Emetine

- cross-resistance studies, 18, 136

## End-plate

- current
  - acceleration of decay time by phencyclidine, 18, 167
  - miniature, production in response to anatoxin-a, 18, 384
  - peak amplitude depressed, 17, 172

## Energy

- interaction, with water: eseroline and morphine, 18, 461

## Enzyme

- deficiency disease: L-gulonolactone oxidase in scurvy (guinea pig), 18, 326
- histamine metabolizing, inhibition by lipid-soluble anticancer folate antagonists, 18, 100
- replacement therapy, 18, 326

## EPBP

- effect on fast axoplasmic transport (rat), 17, 56

## Epidermal growth factor receptor

- action of derivatives, 17, 314

## Epidermis

- strips, adenosine-induced alterations in adenosine 3',5'-monophosphate: effect of psoriasis (human, mouse), 18, 49

## Epinephrine

- loss and restoration of sensitivity to (BHK cells), 18, 370

## EPN

- effect on fast axoplasmic transport (rat), 17, 56

## Epoxide

- interaction with cytochrome P-450, 18, 128

## Epoxide hydrolase

- liver nucleoli (rat), 18, 550

## Erythrocytes

- $\beta$ -adrenergic receptor
  - inactivation by N-ethylmaleimide (turkey), 17, 163
  - internalization and receptor subsensitivity (frog), 18, 348
  - (turkey), comparison with  $\beta_1$  and  $\beta_2$  receptors (mammal), 17, 1

## membrane

- Ca<sup>2+</sup> pump adenosinetriphosphatase, effects of calmodulin and phenothiazines (human), 18, 253
  - cholinergic receptors (human), 18, 28
- Erythromycin
- inhibition of propranolol binding, 17, 187
- Eseroline
- and morphine, quantum chemical study, 18, 461
- Estrogen
- interaction with estrogen receptor, 18, 406
  - and metabolites, receptor bound in nucleus of isolated liver cell (rat), 18, 215
- Estrogen receptor
- nuclear translocation *in vitro*, male, 17, 31
- rat
- liver parenchymal cell, male, 17, 31
  - uterus, 18, 406
  - thermal stability when complexed with estrogens or antiestrogens, 18, 406
  - trypsin proteolysis, 18, 406
- Ethanol
- induced fluidization of brain lipid bilayers (mouse), 17, 52
  - tolerance, reversibility, and cross-tolerance (mouse), 17, 52
- Ethanolamine
- derivatives, metabolites: from reduction of metronidazole by xanthine oxidase, 18, 105
  - metabolite, from reduction of metronidazole by xanthine oxidase, 18, 105
- Ethoxycoumarin
- metabolism, cytochrome P-450 isozymes (rabbit), 17, 218
- Ethylene
- destruction of cytochrome P-450, 18, 128, 602
- 4-Ethyl-1-hexene
- destruction of cytochrome P-450, 18, 602
- N-Ethylmaleimide
- inactivation of  $\beta$ -adrenergic receptors, 17, 163
- Ethylnitrosourea
- inhibition of DNA function, 18, 497

## F

## Fat cells

- glycogen synthase activity and phosphatidylinositol labeling, modulation of effect of adrenergic amines by hypothyroidism (rat), 18, 72
- membranes,  $\beta$ -adrenergic receptors: effects of thyroid status, 18, 193
- metabolism, effect of adrenergic action in hypothyroidism (rat), 18, 72

## Fibroblasts

- cyclic AMP escape and cyclic nucleotide phosphodiesterase activities, inhibition by xanthines (cell culture), 18, 57
- kidney, baby (BHK cells), loss and restoration of sensitivity to epinephrine (hamster), 18, 370
- transformed, lung: puromycin aminonucleoside inhibition of RNA synthesis (human), 17, 262

## Field desorption mass spectrometry

- green porphyrins, liver (rat), 18, 602

## Flavin-adenine dinucleotide monooxygenase

- hamster liver nucleus, 18, 588

## Fluorescent antibody staining

- liver nuclei, location of mixed function amine oxidase (hamster), 18, 151

## 5-Fluorodeoxyuridine

- metabolism in tumor cells (human), 18, 513

## 5-Fluorouracil

- effect on
  - nuclear RNA synthesis and methylation (leukemia cells), 17, 245
  - RNA synthesis, 17, 279
- incorporation into 5 S and 4 S RNA (leukemia cells), 17, 245

- 5-Fluorouridine 5'-triphosphate  
effect on RNA transcribed in nuclei *in vitro*, 17, 279
- Flurbiprofen  
binding sites on serum albumin (human), 18, 421
- Flutamide  
effects on nuclear protein phosphokinases and phosphatases of ventral prostate (rat), 17, 212
- Folate  
antagonists, effect on histamine metabolism, 18, 100  
-independent site of action, lipophilic diaminopyrimidine antifolates *in vitro* (human, mouse), 18, 521
- Formycin B  
evaluation, 18, 287

## G

- $\beta$ -Galactosidase  
DNA-directed cell-free synthesis *in vitro* (phage), 18, 497
- Gallamine  
peripheral site ligand, modulation of acetylcholinesterase activity (electric eel), 18, 33
- Gangliosides  
brain, activation of cyclic nucleotide phosphodiesterase, 17, 206
- Gastric acid  
secretion, inhibition by urogastrone derivatives, 17, 314
- Genetics  
aflatoxins B<sub>1</sub> and B<sub>2</sub>, metabolism (mouse, inbred strains), 18, 296
- Glioma cells  
C-6, intact: norepinephrine-dependent protein phosphorylation, 18, 427  
monoamine oxidases, electrophoresis (rat), 17, 199
- Glutathione transferase  
activity, liver: induction by polycyclic aromatic compounds, not associated with *Ah* locus (mouse), 18, 559
- Glycine  
incorporation into cytochrome P-450 heme (rat), 17, 395
- <sup>3</sup>H-Glycogen  
hydrolysis, elicited by histamine (mouse), 17, 301
- Glycogen synthase  
activity, fat cells: modulation of effect of adrenergic amines in hypothyroidism (rat), 18, 72
- Guanethidine  
effects on chromaffin granule function, 18, 606
- Guanine nucleotides  
and high and low affinity states of  $\beta$ -adrenergic receptor, 17, 14  
and receptor affinity, 18, 193
- Guanosine 3',5'-monophosphate  
levels in diaphragm (rat), 17, 73
- Guanosine 5'-triphosphate  
-dependent process, adenylate cyclase inhibition, 18, 598  
effects on thermodynamics of agonist binding, 18, 341  
and receptor affinity, 18, 193
- Guanyl-5'-yl-imidodiphosphate  
and receptor affinity, 18, 193
- L-Gulonolactone oxidase  
implantation in dialysis bag, in ascorbic acid synthesis (guinea pig), 18, 326

## H

- Heart  
atrium: adenylate cyclase system, effect of hypothyroidism (rat), 17, 180  
autonomic receptors, alterations after 6-hydroxydopamine treatment (rat), 18, 185  
cells,  $\beta_1$  and  $\beta_2$  adrenergic receptors responsible for cyclic AMP accumulation (rat), 17, 8  
developing, regulation of ornithine decarboxylase activity: effect of hyperthyroidism (rat), 18, 247  
effect of iodohydroxybenzylpindolol (cat), 17, 328  
<sup>125</sup>I-iodohydroxybenzylpindolol binding (rat), 17, 1

- myocardial membranes, changes in fluidity during hibernation (ground squirrel), 18, 476
- [<sup>3</sup>H]Jouabain-Na,K-adenosinetriphosphatase complex, dissociation during enzyme isolation (rabbit), 18, 259
- particulate fraction, digitalis receptor: progesterone derivatives that bind to (dog), 18, 402
- sarcolemma, taurine binding to (rat), 17, 295
- HeLa S<sub>3</sub> cells  
DNA replication, inhibition by macromycin-I, 18, 491
- Heme  
prosthetic, N-alkylation of, 18, 602
- Hepatocytes, *see* Liver
- Hepatoma cells  
cytotoxic effects of 8-substituted cyclic nucleotide derivatives (rat), 18, 65  
methotrexate toxicity, 17, 105  
monoamine oxidases A and B, electrophoresis (rat), 17, 199  
treatment with methotrexate, modulation of toxicity by thymidine, 18, 281
- Hibernation  
changes in fluidity of myocardial membrane during (ground squirrel), 18, 476
- High pressure liquid chromatography  
separation of metabolites of N-methylcarbazole, 17, 128
- Histamine  
<sup>3</sup>H labeled, high-affinity binding sites in brain (rat), 18, 1  
metabolism, alteration by antifolates, 18, 100  
response, antagonism by phenoxybenzamine: effect of desensitization (guinea pig), 17, 309
- Histamine receptor  
H<sub>1</sub>, mouse brain slices, 17, 301
- Human  
cells *in vitro*, biochemical pharmacology of lipophilic diaminopyrimidine antifolates, 18, 521  
erythrocyte membrane cholinergic receptors, characterization, 18, 28  
lymphoblasts, purine nucleoside phosphorylase, 18, 287  
serum albumin  
binding sites for nonsteroidal anti-inflammatory drugs, 18, 421  
drug binding, interaction between phenytoin and valproate, 18, 237  
specificity of drug binding sites, 18, 157  
tumor cells, metabolism of 5-fluorodeoxyuridine, 18, 513
- Hydantoin  
and metabolites, in metaphase arrest and microtubular polymerization, 17, 275
- N-Hydroxyacetaminophen  
aryllating intermediate from, 18, 536  
mutagenicity (bacteria), 18, 117
- N-Hydroxy-2-acetylaminofluorene  
activation by cumene hydroperoxide-hematin, 17, 233
- N-Hydroxyacetylaryllamine  
mutagenicity, mechanism (bacteria), 18, 117
- 6-Hydroxydopamine  
autoxidation, 18, 594  
treatment, effect on heart autonomic receptors (rat), 18, 185
- 8-Hydroxyethylaminoadenosine 3',5'-monophosphate  
cytotoxic effects in cultured hepatoma cells (rat), 18, 65
- N-Hydroxymethylcarbazole  
formation in liver microsomes (rabbit), 17, 128
- 1-Hydroxy-N-methylcarbazole  
formation in liver microsomes (rabbit), 17, 128
- 2-Hydroxy-N-methylcarbazole  
formation in liver microsomes (rabbit), 17, 128
- 3-Hydroxy-N-methylcarbazole  
formation in liver microsomes (rabbit), 17, 128
- N-Hydroxyphenacetin  
metabolic activation by liver and kidney fractions (hamster, human, mouse, rat), 18, 117

- 8-Hydroxyquinoline**  
aromatic chelator, antimalarial activity, 18, 320
- 5-Hydroxytryptamine**, *see* Serotonin
- Hypertension**  
effect on biochemistry of vascular smooth muscle plasma membrane (rat), 17, 137
- Hyperthyroidism**  
effects on  
fat cell  $\beta$ -adrenergic receptors (rat), 18, 193  
ornithine decarboxylase activity in developing heart (rat), 18, 247
- Hypothalamus**  
synaptosomes: norepinephrine uptake, effect of phthalane and thiophthalane inhibitors (rat), 17, 321
- Hypothyroidism**  
effects on  
cardiac adenylate cyclase system (rat), 17, 180  
fat cell  $\beta$ -adrenergic receptors (rat), 18, 193  
modulation of effect of adrenergic amines on phosphatidylinositol labeling and glycogen synthase activity of fat cells (rat), 18, 72

## I

- Ibuprofen**  
binding sites on serum albumin (human), 18, 421
- Imidazopyridine**  
derivative, inhibition of sodium pump in axons (squid), 17, 350
- Imidazo-(4,5- $\beta$ )-pyridine**  
6-(2,4-dimethoxyphenyl)-, sodium pump inhibition by (squid), 17, 350
- Immunochemistry**  
*N*-acetyltransferase (rabbit), 17, 367
- Immunohistochemistry**  
localization and distribution of NADPH-cytochrome *c* (*P*-450) reductase in liver (rat), 17, 374
- Immunological properties**  
pancreozymin-gastrin family of peptides, interference by dibutyl cyclic GMP (rat), 17, 268
- Imprinting**  
neonatal, and development of cytochrome *P*-450 (rat), 18, 543
- Inhibition**  
adenylate cyclase, by GTP-dependent process, 18, 598  
cholinesterase, with diisopropylfluorophosphate (rat), 17, 24
- [<sup>3</sup>H]Inositol**  
incorporation into salivary gland lipids, effects of substance *P* (rat), 18, 78
- Insulin**  
release, islet cells: effect of quinine (rat), 18, 243
- Interaction energy**  
with water, eseroline and morphine, 18, 461
- Interferon**  
-inducing agents  
effect on cytochrome *P*-450 heme turnover (rat), 17, 395  
polyribonucleosinic acid-polyribocytidylic acid and tilorone, 17, 395
- Internalization**  
 $\beta$ -adrenergic receptor recognition sites, 18, 348
- Intestine**  
calcium-binding protein synthesis, effect of 1,24(R),25-trihydroxy-cholecalciferol (rat), 17, 362  
colon, carcinoma cell line (H 29): neurotensin binding (human), 18, 11  
ileum  
muscarinic receptors (guinea pig), 18, 179  
smooth muscle: blockade of histamine response by phenoxybenzamine, effect of desensitization (guinea pig), 17, 309
- Iodoxybenzylpindolol**  
<sup>125</sup>I labeled, binding  
rat heart, 17, 1  
turkey erythrocyte, 17, 1  
partial agonist, cardiac tissues (cat), 17, 328  
preparation, purification, and localization of iodine (cat), 17, 328

- Ion**  
exchange between agonists and inorganic ions at acetylcholine receptor, 18, 413  
transport, magnesium, 18, 379
- Ionic channel**  
agonist activation  
by anatoxin-a, 18, 384  
inhibition by phencyclidine, 18, 159  
inhibition, 17, 283  
reaction with open and closed, 18, 167  
time course unchanged, 17, 172
- Ionophore**  
X537A, and quinine: effect on calcium uptake in islet cells (rat), 18, 243
- Iron**  
-initiated lipid peroxidation (rat), 17, 400
- Isoprenaline**  
effect on cardiac cAMP in hypothyroidism (rat), 17, 180
- Isoproterenol**  
-sensitive adenylate cyclase in prostate, effects of androgens (rat), 18, 45

## J

- Junction**, *see* Neuromuscular junction

## K

- Kidney**  
fibroblasts (BHK cells), loss and restoration of sensitivity to epinephrine (hamster), 18, 370  
fractions, metabolic activation of *N*-hydroxyphenacetin (hamster, human, mouse, rat), 18, 117  
microsomes, cytochrome *P*-450: induction by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (rabbit), 18, 565

## L

- Leptophos**  
effect on fast axoplasmic transport (rat), 17, 56
- Leukemia cells**  
L1210  
adenosine and RNA methylation, 18, 483  
growth in culture, alterations in methotrexate transport during (mouse), 18, 274  
interaction of carrier-bound methotrexate with (mouse), 17, 382  
nuclear ribosomal RNA and poly(A) RNA synthesis, effect of 5-azacytidine and dihydro-5-azacytidine, 17, 111  
nuclear RNA, comparative effects of 5-azacytidine and dihydro-5-azacytidine, 17, 250  
nuclear RNA synthesis and methylation *in vitro*, effect of 5-fluorouracil, 17, 245
- Lidoflazine**  
inhibition of nitrobenzylthioinosine binding and uridine transport, 18, 40
- Ligand**  
anionic  
binding to albumin fragments, 18, 224  
competitive binding to albumin, quantitative aspects, 18, 230  
binding to  $\beta$ -adrenergic receptor, computer modeling, 17, 14  
peripheral site, modulation of acetylcholinesterase activity by (electric eel), 18, 33
- Ligand-metal**  
complex, association with antimalarial activity of aromatic chelators, 18, 320
- Lipases**  
as probes, monoamine oxidases A and B in intact brain mitochondria (rat), 18, 267
- Lipid**  
bilayers  
brain, chronic ethanol effect (mouse), 17, 52  
perturbation by general anesthetics, 18, 84

- peroxidation, microsomes  
 carbon tetrachloride metabolism and (rabbit, rat), 18, 553  
 initiation by carbon tetrachloride (rat), 17, 408  
 initiation by iron (rat), 17, 400  
 -soluble anticancer folate antagonists, effect on histamine metabolism, 18, 100
- Lipid-protein  
 interactions in monoamine oxidases in brain (rat), 17, 192; 18, 267
- Lithium bromide  
 dissociation of [ $^3\text{H}$ ]ouabain-Na,K-adenosinetriphosphatase complex, 18, 259
- Liver  
*N*-acetyltransferases, immunochemical studies (rabbit), 17, 367  
 cells, embryo: porphyrin-inducing and membrane fluidizing actions of steroids (chicken), 18, 144  
 cytochrome *P*-450  
   heme turnover, effect of interferon inducing agents (rat), 17, 395  
   inactivation by chloramphenicol (rat), 17, 427  
 fractions, metabolic activation of *N*-hydroxyphenacetin (hamster, human, mouse, rat), 18, 117  
 green porphyrins (rat), 18, 602  
 hepatocytes, isolated: protein degradation and synthesis, effects of lysosomotropic amines (rat), 18, 468  
 hepatoma, *see* Hepatoma cells  
 isolated nuclei, effect of 5-fluorouridine 5'-triphosphate on RNA transcribed *in vitro* (rat), 17, 279  
 lobule, distribution of NADPH-cytochrome *c* (*P*-450) reductase: effects of phenobarbital, pregnenolone-16 $\alpha$ -carbonitrile, and 3-methylcholanthrene pretreatments (rat), 18, 304  
 microsomes  
   aerobic, reductive metabolism of metronidazole and ronidazole (rat), 17, 239  
   carbon tetrachloride metabolism and lipid peroxidation (rabbit, rat), 18, 553  
   cytochrome *P*-450, destruction by olefins *in vitro* (rat), 18, 128  
   cytochrome *P*-450, effect of neonatal imprinting (rat), 18, 543  
   cytochrome *P*-450 forms induced by phenobarbital (rabbit), 17, 218  
   lipid peroxidation, role of iron and NADPH (rat), 17, 400  
   lipid peroxidation, stimulation by carbon tetrachloride (rat), 17, 408  
   *N*-methylcarbazole metabolism (mouse, rabbit, rat), 17, 118; (rabbit), 17, 128  
   proteins, binding of benzo[*a*]pyrene metabolites (rat), 18, 529  
 NADPH-cytochrome *c* (*P*-450) reductase distribution (rat), 17, 374  
 nuclei, superoxide production (hamster), 18, 588  
 nucleolus, cytochrome *P*-450 location (rat), 18, 550  
 parenchymal cell  
   male, *in vitro* nuclear translocation of estrogen receptor (rat), 17, 31  
   nucleus, receptor-bound estrogens and metabolites (rat), 18, 215
- Locus  
*Ah*  
 glutathione transferase not associated with (mouse), 18, 559  
 and toxicity of 2,3,7,8-tetrahydrodibenzo-*p*-dioxin (mouse), 17, 86
- Lung  
 cells,  $\beta_1$  and  $\beta_2$  adrenergic receptors responsible for cyclic AMP accumulation (rat), 17, 8  
 fibroblasts, transformed: puromycin aminonucleoside inhibition of RNA synthesis (human), 17, 262  
 microsomes  
   cytochrome *P*-450: induction by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (rabbit), 18, 565  
   two forms of cytochrome *P*-450: quantitation by substrate specificity (rabbit), 17, 415
- Lymphoblasts  
 purine nucleoside phosphorylase deficiency (human), 18, 287
- Lymphocytes  
 culture, potency of hydantoins in metaphase arrest (human), 17, 275
- Lymphoma  
 S49 cells  
   inactivation of  $\beta$ -adrenergic receptors by *N*-ethylmaleimide, 18, 362  
   independent desensitization of  $\beta$ -receptor-regulated events, 18, 379
- Lysolecithin  
 activation of cyclic nucleotide phosphodiesterase, 17, 206
- Lysosomes  
 hepatocytes, effects of amines on protein degradation (rat), 18, 468
- Lysosomotropism  
 amines, in hepatocytes (rat), 18, 468
- M
- Macromomycin  
 DNA damage after treatment with (virus), 17, 388
- Macromomycin-I  
 inhibition of DNA replication (HeLa cells), 18, 491
- Magnesium  
 agonist exchange at receptor, 18, 413  
 ion transport (lymphoma cells), 18, 379  
 $\text{Mg}^{2+}$ , peripheral site ligand activation of acetylcholinesterase activity (electric eel), 18, 33
- MAIQ-1, *see* 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone
- Malaria  
 parasite glycolysis, inhibition by 8-hydroxyquinoline, 18, 320
- Maleimidobenzyltrimethylammonium  
 receptor alkylation with (rat), 17, 149
- Marine worm  
*Lumbriconereis heteropoda*: nereistoxin from, interaction with acetylcholine receptor-ionic channel complex, 17, 172
- Membrane  
 cholinergic receptors, erythrocyte (human), 18, 28  
 excitable, effects of  $\Delta^9$ -tetrahydrocannabinol (frog), 17, 344  
 fluidity  
   adaptation to ethanol, 17, 52  
   changes during hibernation (ground squirrel), 18, 476  
 fluidization, embryo liver cells: association with porphyrin induction (chicken), 18, 144  
 neural, muscarinic receptor: effect of temperature (frog), 17, 141  
 physical state, effect on phosphatidylserine requirement for opiate binding (rat), 17, 290  
 pinealocyte, measurement of serotonin binding (bovine), 18, 438  
 plasma, vascular smooth muscle: effect of hypertension on biochemistry (rat), 17, 137
- $^3\text{H}$ -Mepyramine  
 binding, brain (mouse), 17, 301
- 6-Mercaptopurine ribonucleoside 5'-triphosphate  
 inhibition of RNA polymerase, 18, 503
- 6-Mercaptopurine ribonucleotides  
 effect on DNA-dependent RNA polymerase activity, 18, 503
- 2-Mercaptopuridine-*N*-oxide  
 aromatic chelator, antimalarial activity, 18, 320
- Mescaline  
 analogs  
   molecular potentials, similar to 5-hydroxytryptamine, 18, 455  
   3 and 4 ring positions, 18, 455
- Metabolic activation  
*N*-hydroxyphenacetin, by liver and kidney fractions (hamster, human, mouse, rat), 18, 117
- Metabolism  
 5-fluorodeoxyuridine, in tumor cells (human), 18, 513
- Metabolites  
 benzo[*a*]pyrene, binding to liver microsome proteins (rat), 18, 529
- Metal  
 ions, divalent: actions in prostate gland (mouse), 17, 156
- Metalloprotein oxidases  
 inhibition, and antimalarial activity of aromatic chelators, 18, 320
- Metaphilic effect

- in desensitization effect on blockade of histamine response by phenoxybenzamine (guinea pig), 17, 309
- <sup>35</sup>S-Methionine**  
labeling, proteins (glioma cells), 18, 427
- Methotrexate**  
carrier bound, interactions with L1210 cells (mouse), 17, 382  
comparison with lipophilic diaminopyrimidine antifolates *in vitro* (human, mouse), 18, 521  
cytotoxicity (hepatoma cells), 17, 105  
polyglutamate forms, cytotoxicity (hepatoma cells), 17, 105  
toxicity, modulation by thymidine (cell culture), 18, 281  
transport, growth phase dependence (leukemia cell culture), 18, 274
- 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone**  
ferrous chelate, effects on ribonucleotide reductase (rat), 18, 507
- N-Methylcarbazole**  
metabolism, in liver microsomes (mouse, rabbit, rat), 17, 118; (rabbit), 17, 128
- 3-Methylcholanthrene**  
effects on metabolism of aflatoxins B<sub>1</sub> and B<sub>2</sub> (mouse, inbred strains), 18, 296  
induction of glutathione transferase (mouse), 18, 559  
pretreatment, effect on NADPH-cytochrome c (P-450) reductase distribution in liver lobule (rat), 18, 304
- 1-Methyl-3-isobutylxanthine**  
and analogs, inhibition of fibroblast cyclic AMP escape and cyclic nucleotide phosphodiesterase activities (cell culture), 18, 57
- Methylnitrosourea**  
alkylation and carbamoylation of DNA by, 18, 497  
inhibition of DNA function, 18, 497
- N-Methyl protoporphyrin IX**  
dimethyl ester, in destruction of cytochrome P-450 by olefins, 18, 602
- Metronidazole**  
metabolites from reduction by xanthine oxidase (rat), 18, 105  
reductive metabolism (rat), 17, 239
- Microsomes**  
incubation, inhibition of covalent binding of acetaminophen by ascorbate, 18, 536  
induction of monooxygenase activity by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (mouse), 18, 571
- liver**  
aerobic, reductive metabolism of metronidazole and ronidazole (rat), 17, 239  
carbon tetrachloride metabolism and lipid peroxidation (rabbit, rat), 18, 553  
cytochrome P-450 forms induced by phenobarbital (rabbit), 17, 218  
cytochrome P-450, neonatal imprinting and testosterone hydroxylation in reconstituted system (rat), 18, 543  
lipid peroxidation, role of iron and NADPH (rat), 17, 400  
lipid peroxidation, stimulation by carbon tetrachloride (rat), 17, 408  
N-methylcarbazole metabolism (mouse, rabbit, rat), 17, 118; (rabbit), 17, 128  
proteins: binding of benzo[a]pyrene metabolites (rat), 18, 529  
lung, two forms of cytochrome P-450: quantitation by substrate specificity (rabbit), 17, 415
- Microtubules**  
polymerization, inhibition by hydantoins, 17, 275
- Mitochondria**  
brain, lipid-protein interactions in monoamine oxidases *in situ* (rat), 17, 192; 18, 267
- Mitosis**  
metaphase arrest, potency of hydantoins in, 17, 275
- Mixed function oxidases**  
induction, inhibition, and species differences, 17, 118
- liver**  
microsomes (mouse, rabbit, rat), 17, 118; (rabbit), 17, 128  
nucleoli (rat), 18, 550  
nucleus, location and specific activity (hamster), 18, 151
- N-methylcarbazole metabolism**, 17, 118, 128
- Molecular mechanics**  
digitalis conformation, 17, 43
- Molecular potentials**  
phenethylamines, 18, 455
- Monoamine oxidase**  
A and B  
human platelets, 17, 199  
<sup>3</sup>H-pargylene labeled, electrophoresis, 17, 199  
rat glioma cells and hepatoma cells, 17, 199  
lipid-protein interactions, 17, 192; 18, 267  
rat brain mitochondria *in situ*, 17, 192; 18, 267
- Monooxygenase**  
activity, microsomes: induction by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (mouse), 18, 571  
brain, heme-mediated stimulation (rabbit), 17, 225  
systems, reconstituted: carbon tetrachloride metabolism, 18, 553
- Morphine**  
and eseroline, quantum chemical study, 18, 461
- Mouse**  
inbred strains, genetics of aflatoxins B<sub>1</sub> and B<sub>2</sub> metabolism, 18, 296
- Muscarinic cholinergic receptor**  
frog central nervous system neural membranes, 17, 141
- Muscarinic receptor**  
guinea pig ileum, 18, 179  
inhibition by phencyclidine, 18, 179  
rat brain, 17, 24; 18, 179
- Muscarone**  
receptor saturation, 18, 413
- Muscle**  
sartorius, effect of piperocaine on endplate current (frog), 17, 283
- skeletal**  
diaphragm, effect of xanthines: lack of relationship between phosphodiesterase inhibition and increased twitch tension (rat), 17, 73  
fast, effect of dibucaine on calcium fluxes in sarcoplasmic reticulum vesicles (rabbit), 17, 61  
neuromuscular junction, effects of phencyclidine on electrical excitability and chemosensitive properties (electric ray, frog, rat), 18, 159  
synapses, effect of nereistoxin (frog, rat), 17, 172
- smooth**  
artery and vein, nitroglycerin-induced relaxation, mechanism (dog), 18, 112  
artery, plasma membrane: effect of hypertension on biochemistry (rat), 17, 137  
gizzard, myosin phosphorylation inhibition by modulator interacting agents (chicken), 17, 66  
ileum, blockade of histamine response by phenoxybenzamine, effect of desensitization (guinea pig), 17, 309  
ileum, contraction: comparison of effects of phencyclidine and phencyclidine methiodide (guinea pig), 18, 179  
isolated, uterus: photoaffinity labeling of angiotensin II receptors (rat), 18, 210  
twitch, potentiation by phencyclidine (frog), 18, 159
- Myeloblastosis**  
cells, RNA polymerase: effect of 6-mercaptopurine ribonucleotides, 18, 503
- Myocardium**  
adenosinetriphosphatase activity (ground squirrel), 18, 476  
membranes, changes in fluidity during hibernation (ground squirrel), 18, 476
- Myosin**  
smooth muscle, phosphorylation: inhibition by modulator interacting agents (chicken), 17, 66
- N**
- NADPH**  
and iron, role in microsomal lipid peroxidation (rat), 17, 400

- NADPH-cytochrome *c* (*P*-450) reductase**  
immunohistochemical localization and distribution in liver (rat), 17, 374; 18, 304
- $\beta$ -Naphthoflavone**  
induction of glutathione transferase (mouse), 18, 559
- Naproxen**  
binding sites on serum albumin (human), 18, 421
- Neocarzinostatin**  
DNA damage after treatment with (virus), 17, 388
- Nereistoxin**  
from marine worm, effect on acetylcholine receptor-ionic channel, 17, 172
- Nerve**  
axon, sodium pump, inhibition by AR-L 57 (squid), 17, 350  
optic, effect of delayed neurotoxic organophosphorus esters (rat), 17, 56
- Neuroleptic drugs**  
conformational requirements for activity, 17, 38  
effect on ( $\text{Ca}^{2+} + \text{Mg}^{2+}$ )-adenosinetriphosphatase activity, 18, 253
- Neuromuscular junction**  
activation by anatoxin-a (frog), 18, 384  
effects of  $\Delta^9$ -tetrahydrocannabinol (frog), 17, 344  
skeletal muscle, effects of phencyclidine on electrical excitability and chemosensitive properties (electric ray, frog, rat), 18, 159
- Neuromuscular transmission**  
effects of  $\Delta^9$ -tetrahydrocannabinol (frog), 17, 344  
inhibition by phencyclidine, 18, 159, 167
- Neurotensin**  
and analogs, binding to extraneural and neural receptors (human, rat), 18, 11  
 $^3\text{H}$  labeled: binding to brain synaptic membranes (rat), and colon carcinoma cell line (HT 29) (human), 18, 11
- Neurotoxicity**  
delayed, organophosphorus esters: inhibition of fast axoplasmic transport (rat), 17, 56
- Nicotinic receptor**  
affinity reagents for, 17, 149  
desensitization by anatoxin-a, 18, 384  
disulfides and sulfhydryls of, 17, 149  
electric ray electric organ, 18, 167  
frog neuromuscular junction, 18, 384  
rat brain, 17, 149
- Niridazole**  
immunoregulatory metabolite: 1-thiocarbamoyl-2-imidazolidinone, 18, 313
- Nitrobenzylthioinosine**  
binding, inhibition by dipyridamole and lidoflazine, 18, 40  
inhibition of uridine transport (HeLa cells), 18, 40
- Nitroglycerin**  
-induced relaxation of smooth muscle in blood vessels, mechanism (dog), 18, 112  
lack of metabolism by smooth muscle (dog), 18, 112  
and metabolites, smooth muscle of blood vessels (dog), 18, 112
- Nitro group**  
reduction, relation to biological actions of metronidazole, 18, 105
- Nitroimidazole**  
anion free radical phantom intermediates (rat), 17, 239
- Nitrosophenol**  
from *N*-hydroxyacetaminophen, 18, 536
- Norepinephrine**  
concentration, 5 heart regions: effect of 6-hydroxydopamine treatment (rat), 18, 185  
-dependent protein phosphorylation (glioma cells), 18, 427  
from enzymic conversion of dopamine, production of semidehydroascorbate, 17, 421  
uptake: inhibition by phthalane and thiophthalane, comparison with desipramine, 17, 321
- Nuclear magnetic resonance**  
conformational behavior by, acylcholine analogs, 18, 20
- $^1\text{H}$  Fourier transform, structural identification of metabolites of *N*-methylcarbazole, 17, 128
- Nucleolus**  
liver, cytochrome *P*-450 location (rat), 18, 550  
mixed function oxidases (rat), 18, 550
- Nucleoside**  
transport, inhibition by dipyridamole and nitrobenzylthioinosine (HeLa cells), 18, 40
- Nucleus**  
liver  
parenchymal cell, isolated: receptor-bound estrogens and metabolites (rat), 18, 215  
superoxide production (hamster), 18, 588  
mixed function amine oxidase, liver: location and specific activity (hamster), 18, 151  
translocation, *in vitro*: estrogen receptor in male (rat), 17, 31
- O**
- Olefins**  
destruction of cytochrome *P*-450 by, 18, 602
- Opiate**  
binding, phosphatidylserine requirement for (rat), 17, 290
- Opiate receptor**  
mouse vas deferens, 18, 395  
multiple, lack of cross-tolerance, 18, 395
- Optic nerve**  
effect of delayed neurotoxic organophosphorus esters (rat), 17, 56
- Organophosphorus esters**  
effect on fast axoplasmic transport (rat), 17, 56
- Ornithine decarboxylase**  
activity, regulation in developing heart: effect of hyperthyroidism (rat), 18, 247
- Ouabain**  
-induced changes in tertiary and quaternary conformations of ( $\text{Na}^+ + \text{K}^+$ )-activated adenosinetriphosphatase, 18, 53  
radioreceptor binding assay, 18, 402  
[ $^3\text{H}$ ]Ouabain- $\text{Na,K}$ -adenosinetriphosphatase complex, dissociation during enzyme isolation, heart (rabbit), 18, 259
- P**
- P*-286, *see N,N*-Diisopropyl-*N'*-isoamyl-*N'*-diethylaminoethylurea
- Palmitic acid**  
inhibition of propranolol binding, 17, 187
- Pancreas**  
exocrine, plasma membranes: pancreozymin, interaction with dibutyl cyclic GMP (rat), 17, 268  
islets, isolated: effect of quinine on insulin release and calcium uptake (rat), 18, 243
- Pancreozymin**  
interaction with dibutyl cyclic GMP (rat), 17, 268
- Paraoxon**  
inhibition of mutagenicity, *N*-hydroxyphenacetin (bacteria), 18, 117
- Parathion**  
effect on fast axoplasmic transport (rat), 17, 56
- Parathyroid**  
cells, dispersed: characterization of dopamine receptors (bovine), 18, 335
- Parathyroid hormone**  
release, regulation (bovine), 18, 335
- $^3\text{H}$ -Pargyline  
-labeled monoamine oxidases A and B, electrophoresis, 17, 199
- Parotid**  
acinar cells  
 $\alpha$ -adrenergic regulation of cholinergic responses (rat), 18, 356  
potassium release (rat), 18, 356  
glands, lipids: incorporation of [ $^3\text{H}$ ]inositol, effects of substance P (rat), 18, 78



- Partition coefficients**  
lipid/water, and antimalarial activity of aromatic chelators, 18, 320
- PCILO**  
method, conformational analysis of *N*-( $\beta$ -acetoxyethyl)pyridinium ion, 18, 331  
perturbative configuration interaction using localized orbital method, 17, 339
- PCP, see Phencyclidine**
- Pentobarbital**  
cross-tolerance with ethanol (mouse), 17, 52
- Perhydrohistrionicotoxin**  
binding  
to electric organ membranes (electric ray), 17, 283  
to electrophax membranes, effect of nereistoxin, 17, 172  
inhibition by phencyclidine, 18, 167
- Persantine, see Dipyrindamole**
- pH**  
extracellular, effect on control of blood platelet serotonin secretion (rat), 17, 356
- Phage, see Bacteriophage**
- Phencyclidine**  
effects on electrical excitability and chemosensitive properties of neuromuscular junction of skeletal muscle (electric ray, frog, rat), 18, 159  
inhibition of peak amplitude end-plate current, 18, 167  
and phencyclidine methiodide, comparison of interactions with muscarinic receptors, 18, 179
- Phencyclidine methiodide**  
and phencyclidine, comparison of interactions with muscarinic receptors, 18, 179
- Phenethylamines**  
hallucinogenic potency, 18, 455
- Phenobarbital**  
induction of cytochrome *P*-450 forms (rabbit), 17, 218  
-like inducer of microsomal monooxygenase activity: 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (mouse), 18, 571  
pretreatment, effect on NADPH-cytochrome *c* (*P*-450) reductase distribution in liver lobule (rat), 18, 304
- Phenothiazines**  
inhibition of ( $\text{Ca}^{2+} + \text{Mg}^{2+}$ )-adenosinetriphosphatase, 18, 253
- Phenoxybenzamine**  
antagonism of histamine response by, effect of desensitization (guinea pig), 17, 309
- Phenylephrine**  
effect on cardiac cAMP in hypothyroidism (rat), 17, 180
- Phenytion**  
interaction with valproate, binding to serum albumin (human), 18, 237  
in metaphase arrest and microtubular polymerization, 17, 275  
perturbation of lipid bilayers, 18, 84
- Pheochromocytoma**  
clonal cell line, tyrosine hydroxylase (rat), 17, 79
- Phosphatidylinositol**  
labeling, effect of adrenergic amines: modulation in hypothyroidism (rat), 18, 72  
turnover in salivary glands, effects of substance P (rat), 18, 78
- Phosphatidylserine**  
requirement for opiate binding (rat), 17, 290
- Phosphodiesterase**  
cyclic nucleotide, *see* Cyclic nucleotide phosphodiesterase  
inhibition by xanthines (cell culture), 18, 57
- Phospholipase A<sub>2</sub>**  
effect on opiate binding to brain membranes (rat), 17, 290
- Phospholipids**  
brain membranes, in opiate binding (rat), 17, 290
- Phosphorylation**  
myosin, inhibition by modulator interacting agents (chicken), 17, 66
- Photoaffinity labeling**  
angiotensin II receptors, 18, 210
- Phthalane**  
inhibitors of norepinephrine uptake, 17, 321
- Phytohemagglutinin**  
stimulation of lymphocytes, potency of hydantoins in metaphase arrest (human), 17, 275
- Pigments**  
hepatic green, formation after olefin administration (rat), 18, 128, 602
- Pinealocytes**  
isolation (bovine), 18, 438, 447
- Piperocaine**  
effects on  
acetylcholine receptor ion channel complex (electric ray), 17, 283  
endplate current, muscle (frog), 17, 283
- Platelets**  
blood: serotonin secretion, effect of extracellular pH (rat), 17, 356  
monoamine oxidases, electrophoresis (human), 17, 199
- Polyadenylic acid**  
in RNA: synthesis, effect of 5-azacytidine and dihydro-5-azacytidine (leukemia cells), 17, 111
- Polymerization**  
microtubules, inhibition by hydantoins, 17, 275
- Polyribonucleosinic acid-polyribocytidylic acid**  
effect on cytochrome *P*-450 heme turnover (rat), 17, 395
- Porphyrin**  
*N*-alkylated, 18, 602  
induction, association with membrane fluidization, 18, 144
- Potassium**  
channel blockade by phencyclidine, 18, 159
- Potential**  
action, prolongation by phencyclidine, 18, 159  
molecular, phenethylamines, 18, 455
- Pregnenolone-16 $\alpha$ -carbonitrile**  
pretreatment, effect on NADPH-cytochrome *c* (*P*-450) reductase distribution in liver lobule (rat), 18, 304
- Presynaptic regulation**  
tyrosine hydroxylase activity in striatal synaptosomes by dopamine analogs (rat), 18, 91
- Progesterone**  
derivatives, and digitalis receptor binding: structure-activity relationships, 18, 402
- Progestins**  
digitalis receptor binding, 18, 402
- PROPHET, see Computer**
- Propidium**  
peripheral site ligand, modulation of acetylcholinesterase activity (electric eel), 18, 33
- Propranolol**  
binding, distribution between serum proteins (human), 17, 187
- Prostate**  
gland, inhibition of androgen receptors by divalent metal ions (mouse), 17, 156  
isoproterenol-sensitive adenylate cyclase system, effects of androgens (rat), 18, 45  
ventral  
nuclear protein phosphokinases and phosphatases, effects of antiandrogens (rat), 17, 212  
phosphorylation of chromatin proteins, effects of antiandrogens (rat), 17, 212
- Protein**  
activator, calcium-dependent, 17, 206  
antitumor, antibiotic: macromycin-I, inhibition of DNA replication (HeLa cells), 18, 491  
calcium  
-binding, intestine: effect of 1,24(R),25-trihydroxycholecalciferol (rat), 17, 362  
-regulated modulator, interacting agents: myosin phosphorylation inhibition (chicken), 17, 66

- degradation in hepatocyte lysosomes, inhibition by amines (rat), 18, 468
- intermediate filament, phosphorylation of (glioma cells), 18, 427
- microsomes, liver: binding of benzo[a]pyrene metabolites (rat), 18, 529
- phosphorylation
  - in blood platelets, effect of extracellular pH (rat), 17, 356
  - norepinephrine-dependent (glioma cells), 18, 427
- serum, propranolol binding (human), 17, 187
- synthesis
  - in hepatocytes, effects of amines (rat), 18, 468
  - inhibitors, 18, 136
- Protein kinase
  - calcium stimulated, smooth muscle (chicken), 17, 66
- Protein phosphatase
  - nucleus, ventral prostate: effects of antiandrogens (rat), 17, 212
- Protein phosphokinase
  - nucleus, ventral prostate: effects of antiandrogens (rat), 17, 212
- Psoriasis
  - epidermal strips, effects on adenosine-induced alterations in adenosine 3',5'-monophosphate (human), 18, 49
- Purine nucleoside phosphorylase
  - inhibition, 18, 287
- Puromycin aminonucleoside
  - inhibition of RNA synthesis, mechanism, 17, 262
  - metabolism (fibroblasts), 17, 262

## Q

- QNB, *see* [<sup>3</sup>H]Quinuclidinyl benzilate
- Quantal release
  - effects of  $\Delta^9$ -tetrahydrocannabinol (frog), 17, 344
- Quantum chemistry
  - eseroline and morphine, 18, 461
- Quinine
  - effect on insulin release and calcium ionophoresis in islet cells (rat), 18, 243
- [<sup>3</sup>H]Quinuclidinyl benzilate
  - binding to muscarinic receptors (rat), 17, 24
- dL-[<sup>3</sup>H]Quinuclidinyl benzilate
  - binding
    - erythrocyte membranes (human), 18, 28
    - inhibition by phencyclidine, 18, 179

## R

- Radical
  - free, formation: in reductive glycosidic cleavage of anthracycline antibiotics, 17, 95
- Receptor
  - activation by agonist, 18, 413
  - agonist-affinity shift, 18, 193
  - binding, estimates of epidermal growth factor and ligand affinities, 17, 314
  - bound estrogens and metabolites in nucleus of isolated liver cell (rat), 18, 215
  - central dopamine antagonists, active conformation, 17, 38
  - extraneural and neural, neurotensin binding: biological activity and structure-activity relationships, 18, 11
  - heterogeneity, functional, 18, 362
  - mediated GTP-dependent process, adenylate cyclase inhibition (rat), 18, 596
  - physical state, effect on opiate binding (rat), 17, 290
  - saturation by decamethonium, muscarone, and  $\alpha$ -bungarotoxin, 18, 413
- Red blood cells, *see* Erythrocytes
- Reduction
  - cytidine 5'-diphosphate by ribonucleotide reductase, kinetics, 18, 507
  - metronidazole, by xanthine oxidase: metabolites from, 18, 105

- Regulation
  - presynaptic, tyrosine hydroxylase activity in striatal synaptosomes by dopamine analogs (rat), 18, 91
- Relaxation
  - nitroglycerin induced, isolated blood vessels: absence of metabolite formation (dog), 18, 112
- 1- $\beta$ -D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
  - inhibition of human lymphoblast purine nucleoside phosphorylase, 18, 287
- Ribonucleoside-diphosphate reductase
  - from Novikoff tumor, effects of ferrous chelate of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (rat), 18, 507
- Ribonucleotide reductase, *see* Ribonucleoside-diphosphate reductase
- RNA
  - liver, transcribed in nuclei *in vitro* (rat), 17, 279
  - methylation, effects of
    - 5-azacytidine and dihydro-5-azacytidine (leukemia cells), 17, 250
    - 5-fluorouracil (leukemia cells), 17, 245
  - nuclear
    - comparative effects of 5-azacytidine and dihydro-5-azacytidine (leukemia cells), 17, 250
    - methylation, effect of adenosine and cordycepin (cell culture), 18, 483
    - methylation, effect of 5-azacytidine and dihydro-5-azacytidine (leukemia cells), 17, 111
  - polyadenylic acid-containing: synthesis *in vitro*, effect of 5-azacytidine and dihydro-5-azacytidine (leukemia cells), 17, 111
  - ribosomal: synthesis *in vitro*, effect of 5-azacytidine and dihydro-5-azacytidine (leukemia cells), 17, 111
  - synthesis
    - effect of 5-fluorouracil (leukemia cells), 17, 245
    - inhibition by puromycin aminonucleoside, mechanism of action (human), 17, 262
- RNA polymerase
  - DNA dependent, inhibition by 6-mercaptopurine ribonucleotides (bacteria, chicken), 18, 503
  - liver, isolated nuclei (rat), 17, 279
- Ronidazole
  - reductive metabolism (rat), 17, 239
- Rubidium
  - ouabain-sensitive <sup>86</sup>Rb influx into axon, inhibition by AR-L 57 (squid), 17, 350

## S

- Salivary glands
  - salivation and phosphatidylinositol turnover, effect of substance P (rat), 18, 78
- Sarcolemma
  - heart, taurine binding to (rat), 17, 295
- Sarcoplasmic reticulum
  - vesicles, effect of dibucaine on calcium fluxes (rabbit), 17, 61
- Scatchard
  - model
    - computer analysis: ligand competitive binding to albumin, 18, 230
    - ligand binding to albumin fragments, 18, 224
- Scurvy
  - prevention by implantation of dialysis bag containing L-gulonolactone oxidase (guinea pig), 18, 326
- Semidehydroascorbate
  - product of enzymic conversion of dopamine to norepinephrine, 17, 421
- Semidehydroascorbate reductase
  - coupling to dopamine  $\beta$ -hydroxylase, 17, 421
- Semiquinone
  - free radical, 18, 594
- Semiquinone-imine
  - free radical, 6-aminodopamine, 18, 594
- Serotonin
  - mescaline analogs, similar to, 18, 455

- secretion, blood platelets: effect of pH (rat), 17, 356
- uptake
- characterization and kinetics, 18, 447
  - effects of temperature, ions, and drugs, 18, 447
  - system, evidence for: pinealocyte suspensions (bovine), 18, 438
- Serum
- albumin, *see* Albumin, serum
  - proteins, propranolol binding (human), 17, 187
- Site
- responsible for binding,  $\beta$ -adrenergic drugs, 17, 339
- Skin
- epidermal strips, adenosine-induced alterations in adenosine 3',5'-monophosphate (human, mouse), 18, 49
- Sodium
- Na-Na exchange in axon (squid), 17, 350
  - ouabain-sensitive  $^{22}\text{Na}$  efflux from axon, inhibition by AR-L 57 (squid), 17, 350
  - pump, inhibition by cardioactive drug (squid), 17, 350
- Sodium iodide
- dissociation of [ $^3\text{H}$ ]ouabain-Na,K-adenosinetriphosphatase complex, 18, 259
- Spin trapping
- cumene hydroperoxyl radical, 17, 233
  - superoxide, 17, 239
- Stability
- thermal, ligand-mediated: estrogen receptor when complexed with estrogens or antiestrogens, 18, 406
- Steroids
- porphyrin-inducing and membrane fluidizing actions, in embryo liver cells (chicken), 18, 144
- Structure-activity relationships
- acetylcholine derivatives, 18, 20
  - digitalis analogs, 17, 43
  - emetine, cryptopleurine, and tylocrebrine, 18, 136
  - eseroline and morphine, 18, 461
  - mescaline analogs, 18, 455
  - neuroleptic drugs, 5-aryltetrahydro- $\gamma$ -carboline series, 17, 38
  - neurotensin and analogs, 18, 11
  - phthalane and thiophthalane inhibitors of norepinephrine uptake, 17, 321
  - progesterone derivatives, and digitalis receptor binding, 18, 402
- Styrene, 7,8-oxide
- substrate for liver glutathione transferase (mouse), 18, 559
- Subcellular fractionation
- phosphopolypeptides (glioma cells), 18, 427
- Substance P
- and related peptides, effects on salivation and phosphatidylinositol turnover in salivary glands (rat), 18, 78
- Substance P receptor
- assay for activity, screening procedure for potential agonists and antagonists (rat), 18, 78
  - rat salivary glands, 18, 78
- Superoxide
- formation
    - by actinomycin D and spin-labeled derivatives, 17, 432
    - in metronidazole reductive metabolism (rat), 17, 239  - production by liver nuclei (hamster), 18, 588
- Superoxide dismutase
- hamster liver nucleus, 18, 588
- Synaptosomes
- hypothalamus: norepinephrine uptake, effect of phthalane and thiophthalane inhibitors (rat), 17, 321
  - striatum, presynaptic regulation of tyrosine hydroxylase activity by dopamine analogs (rat), 18, 91
- T
- Tachyphylaxis
- to epinephrine (BHK cells), 18, 370
- Taurine
- binding sites of cardiac sarcolemma, role in calcium regulation (rat), 17, 295
- TCDD, *see* 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
- Temperature
- acclimation, neural membrane muscarinic sites (frog), 17, 141
  - effects on binding, 18, 341
- Testosterone
- hydroxylation, reconstituted system: by cytochrome *P*-450 from neonatally imprinted rats, 18, 543
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
- effects on metabolism of aflatoxins B<sub>1</sub> and B<sub>2</sub> (mouse, inbred strains), 18, 296
  - induction of
    - cytochrome *P*-450 in kidney and lung microsomes (rabbit), 18, 565
    - glutathione transferase (mouse), 18, 559  - toxicity, segregation with *Ah* locus (mouse), 17, 86
- Tetragastrin
- interaction with dibutyryl cyclic GMP (rat), 17, 268
- $\Delta^9$ -Tetrahydrocannabinol
- effects on excitable membranes and neuromuscular transmission (frog), 17, 344
- Theophylline
- inhibition of adenosine-induced increase in cyclic AMP levels in epidermal strips (human, mouse), 18, 49
- Thermodynamics
- of binding, agonist and antagonist interactions with  $\beta$ -adrenergic receptors, 18, 341
  - $^{125}\text{I}$ -iodohydroxybenzylpindolol binding in erythrocyte (turkey) and heart (rat), 17, 1
- 1-Thiocarbamoyl-2-imidazolidinone
- immunoregulation, 18, 313
  - immunosuppression, 18, 313
  - isolation, characterization, and synthesis, 18, 313
- Thiophthalane
- inhibitors of norepinephrine uptake, 17, 321
- Thioredoxin
- in cytidine 5'-diphosphate reduction by ribonucleotide reductase, kinetics, 18, 507
- Thymidine
- modulation of methotrexate toxicity (cell culture), 18, 281
- Thymus
- DNA, incorporation of trifluorothymidine in a cell-free system: no chain termination (bovine), 18, 148
  - DNA polymerase- $\alpha$ , regulation (bovine), 17, 256
- Thyroid
- effect on ornithine decarboxylase activity in developing heart (rat), 18, 247
  - status, effects on fat cell  $\beta$ -adrenergic receptors (rat), 18, 193
- Tilorone
- effect on cytochrome *P*-450 heme turnover (rat), 17, 395
- Tissue
- histamine levels, effect of lipid-soluble anticancer folate antagonists, 18, 100
- Tolerance
- ethanol, reversibility and cross-tolerance (mouse), 17, 52
  - lack of dependence, multiple opiate receptors in vas deferens (mouse), 18, 395
- Transglutaminase
- role in internalization of  $\beta$ -adrenergic receptor recognition sites, 18, 348
- Translocation
- nucleus, *in vitro*: estrogen receptor in male (rat), 17, 31
- Transport
- alterations, methotrexate: growth phase dependence (leukemia cell culture), 18, 274
  - axoplasm, fast: inhibition by delayed neurotoxic organophosphorus esters (rat), 17, 56
  - ion, magnesium, 18, 379

- nucleoside, inhibition by dipyridamole and nitrobenzylthioinosine (HeLa cells), 18, 40
- Tri-*o*-cresyl phosphate  
effect on fast axoplasmic transport (rat), 17, 56
- Tricyclic inhibitors  
of norepinephrine uptake, 17, 321
- Trifluoperazine  
effect on  $(Ca^{2+} + Mg^{2+})$ -adenosinetriphosphatase activity, 18, 253
- Trifluorothymidine  
incorporation into thymus DNA in a cell-free system: no chain termination (bovine), 18, 148
- 1,24(R),25-Trihydroxycholecalciferol  
effect on intestinal calcium-binding protein (rat), 17, 362
- d*-Tubocurarine  
peripheral site ligand, modulation of acetylcholinesterase activity (electric eel), 18, 33
- Tumor  
Novikoff, ribonucleotide reductase from (rat), 18, 507
- Tylocrebrine  
cross-resistance studies, 18, 136
- Tyrosine hydroxylase, *see* Tyrosine 3-monooxygenase
- Tyrosine 3-monooxygenase  
pheochromocytoma cells, purification and characterization (rat), 17, 79  
presynaptic regulation, by dopamine analogs, 18, 91  
rat striatal synaptosomes, 18, 91
- U
- Uracil-DNA glycosylase  
role in 5-fluorodeoxyuridine metabolism in tumor cells (human), 18, 513
- Uridine  
transport, inhibition by nitrobenzylthioinosine, dipyridamole, and lidoflazine (HeLa cells), 18, 40
- Urogastrone receptor  
action of derivatives, 17, 314
- Uterus  
estrogen receptor, thermal stability when complexed with estrogens or antiestrogens (rat), 18, 406  
isolated smooth muscle, photoaffinity labeling of angiotensin II receptors (rat), 18, 210
- V
- Valproate  
interaction with phenytoin, binding to serum albumin (human), 18, 237
- Vas deferens  
multiple opiate receptors, lack of cross-tolerance on (mouse), 18, 395
- Verapamil  
taurine antagonist (rat), 17, 295
- Vesicles  
sarcoplasmic reticulum, effect of dibucaine on calcium fluxes (rabbit), 17, 61
- Viruses  
simian virus 40, treatment with antitumor drugs: DNA damage, 17, 388
- Vitamin C, *see* Ascorbic acid
- W
- Water  
interaction energy with: eseroline and morphine, 18, 461
- X
- Xanthine  
derivatives  
enhancement of diaphragm contraction (rat), 17, 73  
phosphodiesterase inhibition by (rat), 17, 73  
inhibition of fibroblast cyclic AMP escape and cyclic nucleotide phosphodiesterase activities (cell culture), 18, 57
- Xanthine oxidase  
bovine milk, 17, 95  
interactions with anthracycline antibiotics, 17, 95  
milk, metabolites from reduction of metronidazole by, 18, 105
- Z
- Zinc  
ions, actions in prostate gland (mouse), 17, 156  
 $Zn^{2+}$ , peripheral site ligand modulation of acetylcholinesterase activity (electric eel), 18, 33

Statement of ownership, management and circulation required by the Act of October 23, 1962, Section 4369, Title 39, United States Code; of

#### MOLECULAR PHARMACOLOGY

Published bimonthly by Academic Press, Inc., 111 Fifth Avenue, New York, N. Y. 10003. Number of issues published annually: 6. Editor: Norman Kirshner, Duke University Medical Center, Durham, N. C. 27710.

Owned by American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20014. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages or other securities: None.

Paragraphs 2 and 3 include, in cases where the stockholder or security holder appears upon the books of the company as trustee or in any other fiduciary relation, the name of the person or corporation for whom such trustee is acting, also the statements in the two paragraphs show the affiant's full knowledge and belief as to the circumstances and conditions under which stockholders and security holders who do not appear upon the books of the company as trustees, hold stock and securities in a capacity other than that of a bona fide owner. Names and addresses of individuals who are stockholders of a corporation which itself is a stockholder or holder of bonds, mortgages or other securities of the publishing corporation have been included in paragraphs 2 and 3 when the interests of such individuals are equivalent to 1 percent or more of the total amount of the stock or securities of the publishing corporation.

Total no. copies printed: average no. copies each issue during preceding 12 months: 1806; single issue nearest to filing date: 1773. Paid circulation (a) to term subscribers by mail, carrier delivery or by other means: average no. copies each issue during preceding 12 months: 1362, single issue nearest to filing date: 1294. (b) Sales through agents, news dealers, or otherwise: average no. copies each issue during preceding 12 months: 0; single issue nearest to filing date: 0. Free distribution by mail, carrier delivery, or by other means: average no. copies each issue during preceding 12 months: 78; single issue nearest to filing date: 78. Total no. of copies distributed: average no. copies each issue during preceding 12 months: 1430; single issue nearest to filing date: 1372.

(Signed) Houston Baker, Executive Secretary

***A New Rapid Communication Journal...***



# **BIOCHEMISTRY INTERNATIONAL**



**Published for the INTERNATIONAL UNION OF BIOCHEMISTRY  
by ACADEMIC PRESS**

**Editor-in-Chief: A. W. LINNANE**

Department of Biochemistry, Monash University, Clayton, Victoria, 3168, Australia

## **EDITORIAL BOARD**

**G. BERNARDI**  
Institut de Recherche en  
Biologie Moléculaire,  
Université Paris VII,  
2 Place Jussieu,  
F 75221, Paris, France

**J. CARBON**  
Department of Biological  
Sciences,  
University of California,  
Santa Barbara, California  
93106, U.S.A.

**M. J. CRUMPTON**  
Imperial Cancer Research  
Fund Laboratories,  
P.O. Box 123,  
Lincoln's Inn Fields,  
London, WC2A 3PX, England

**H. M. GOODMAN**  
Department of Biochemistry  
and Biophysics,  
University of California,  
San Francisco,  
California, 94143, U.S.A.

**Y. HATEFI**  
Department of Biochemistry  
Scripps Clinic & Research  
Foundation,  
10666 North Torrey Pines Road,  
La Jolla, California 92037, U.S.A.

**O. HAYAISHI**  
Department of Medical  
Chemistry,  
Kyoto University,  
Faculty of Medicine,  
Sakyo-ku, Kyoto 606, Japan

**N. HILSCHMANN**  
Max-Planck-Institut für  
Experimentelle Medizin  
Abt. Immunchemie,  
Hermann-Rein-Strasse 3,  
D-3400, Göttingen,  
Federal Republic of Germany

**U. Z. LITTAUER**  
Department of Neurobiology,  
Weizmann Institute of Science  
Rehovot, Israel

**R. MONIER**  
Institut de Recherches  
Scientifique,  
Sur le Cancer,  
B.P.8, 94800, Villejuif, France

**I. H. PASTAN**  
Laboratory of Molecular  
Biology,  
National Cancer Institute,  
National Institutes of Health,  
Bethesda, Maryland 20205,  
U.S.A.

**R. N. PERHAM**  
Department of Biochemistry,  
University of Cambridge,  
Tennis Court Road,  
Cambridge, CB2 1QW, England

**S. E. SEVERIN**  
Department of Biochemistry  
School of Biology,  
Moscow State University,  
117234, Moscow, B-234, USSR

**F. R. WHATLEY**  
Department of Botany,  
University of Oxford,  
South Parks Road,  
Oxford, OXI 3RA, England

**W. J. WHELAN**  
Department of Biochemistry  
University of Miami School  
of Medicine,  
P.O. Box 016129  
Miami, Florida 33101, U.S.A.

**H.-G. WITTMANN**  
Max-Planck-Institut für  
Molekulare Genetik,  
D-1000 Berlin 33, (Dahlem)  
Germany

**K. YAGI**  
Institute of Biochemistry,  
Faculty of Medicine,  
University of Nagoya  
Nagoya 466, Japan

*Biochemistry International* is a new journal for the rapid publication of short communications in the overall area of biochemistry. It is published by ACADEMIC PRESS on behalf of the International Union of Biochemistry.

*Biochemistry International* publishes short papers reporting new and significant observations in the field. It is also intended to publish mini-reviews in topical areas.

For detailed information on preparation of manuscripts please contact any one of the editors or Academic Press.

Published monthly

Subscription: Volumes 2-3 1981, (12 issues) \$170.00 ISSN: 0158-5231

Subscriptions are for the calendar year and payable in advance.

## **Academic Press, Inc.**

*A Subsidiary of Harcourt Brace Jovanovich, Publishers*

NEW YORK SYDNEY LONDON TORONTO SAN FRANCISCO

111 FIFTH AVENUE, NEW YORK, N.Y. 10003/ 24-28 OVAL ROAD, LONDON NW1 7DX

## Polymeric Drugs

Edited by L. GUY DONARUMA and OTTO VOGL

CONTENTS: A. Zaffaroni and P. Bensen, Controlled Chemotherapy Through Macromolecules. N. M. Weinschenker, Polymeric Additives for Food. G. Manecke, Immobilized Enzymes. N. A. Plate, Synthesis and Some Properties of Antithrombogenic Polymers. D. Tirrell *et al.*, Polymers with Ultraviolet Absorbers as Functional Groups. K. Takemoto, Recent Problems Concerning Functional Monomers and Polymers Containing Nucleic Acid Bases. J. Kálal *et al.*, Synthetic Polymers in Chemotherapy: General Problems. C. M. Samour, Polymeric Drugs in the Chemotherapy of Microbial Infections. G. G. Allan *et al.*, Polymeric Drugs for Plants. J. Burton *et al.*, Solubility and Lipophilicity Relationships in the Design of Renin Inhibitors. E. P. Goldberg, Polymeric Affinity Drugs for Cardiovascular, Cancer, and Urolithiasis Therapy. R. M. Ottenbrite *et al.*, Biological Activity of Polycarboxylic Acid Polymers. H. B. Levy, Polymers as Interferon Inducers. E. H. Schacht *et al.*, Synthesis and Characterization of 2,6-Dichlorobenzaldehyde-Generating Polymers. L. G. Donaruma *et al.*, Potential Structure-Activity Relationships, Indigenous to Polymer Systems (1).

1978. 400 pp

## Cell Surface Carbohydrate Chemistry

Edited by ROBERT E. HARMON

FROM THE PREFACE:

"This volume is a permanent record of the Cell Surface Carbohydrate Chemistry Symposium held on September 1 and 2, 1976 in conjunction with the American Chemical Society Centennial Meeting in San Francisco. . . .

"The main objective of this symposium was to bring together carbohydrate chemists and cell biologists who were involved in or interested in studying the oligosaccharides which make up the glycoproteins and glycolipids found in the cell membranes of normal or neoplastic cells."

1978. 384 pp

SECOND EDITION

## Principles of Psychopharmacology

A Textbook for Physicians, Medical Students, and Behavioral Scientists

Editors: WILLIAM G. CLARK and JOSEPH del GIUDICE

SECTION HEADINGS: Introduction. Some Basic Anatomical, Biochemical and Physiological Considerations. Chemistry, Metabolism and Classification of Psychotropic Drugs. Pharmacological and Physiological Bases of Psychopharmacology. Genetic and Environmental Aspects of Drugs and Behavior. Psychopharmacologic Drug Design and Research Problems with Humans. Toxicology and Adverse Side Effects of Psychotropic Drugs and Their Management. Psychopharmacotherapy. Special Problems in Psychopharmacology. General Medical Use of Psychotropic Drugs. Substance Abuse. Epilogue and Foreglimpse.

1978. about 950 pp

AP 7832

**ACADEMIC PRESS, INC.**

A Subsidiary of Harcourt Brace Jovanovich, Publishers

111 FIFTH AVENUE, NEW YORK, N.Y. 10003

24-28 OVAL ROAD, LONDON NW1 7DX

## INSTRUCTIONS TO AUTHORS

*Molecular Pharmacology* will publish the results of investigations that shed significant light on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly, to include chemical agents that selectively modify biological function.

Suitable papers are those which describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not regarded as appropriate for publication.

Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture; conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis; pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species; drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and transport of drug molecules between biological compartments.

"Short Communications" will be considered for rapid publication if their subject matter lies within the scope of the Journal, if they are concise, and if they are considered to be of sufficiently immediate importance to the work of other investigators to justify accelerated publication. They may contain experimental observations, theoretical material, or significant comment upon published investigations.

**Page Charges.** Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment will always be considered entirely voluntary.

**Submission of manuscript.** Manuscripts are published in English only and should be sent to the Editor, Dr. Norman Kirshner, Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710, U.S.A. Manuscripts should be typewritten double spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit three complete copies of the manuscript and three copies of each figure, plus one original drawing or photograph of each figure. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to adequately document the manuscript. In most instances 30 references or less should suffice.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

**Organization and style of manuscripts.** The policy of the Journal

is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 246, pp. 1-8, January 10, 1971). Drugs must be referred to by their genetic or chemical names throughout the text, but may be identified by trade name in parenthesis or a footnote. The systematic name and number given by the commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary preceded by authors' names and title of article. For example: >

### SUMMARY

DAIRMAN, W., AND S. UDENFRIEND. Studies on the mechanism of the L-3,4-dihydroxyphenylalanine-induced decrease in tyrosine hydroxylase activity. *Mol. Pharmacol.* 8: 293-299 (1972).

(5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text, including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baue and

W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13: 606-614 (1977). 2. Sandler, M. Variations in monoamine oxidase activity in some human disease states, in *Monoamine Oxidase and Its Inhibition*. Ciba Foundation Symposium 39. Elsevier, Amsterdam, 327-340 (1976). (7). Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

**Tables.** These should be numbered with arabic numerals and designed to fit the single-column width or the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

**Figures.** These should be numbered with arabic numerals. Each of the three manuscript copies should contain all the figures, but only the original set need be of quality suitable for reproduction.

These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (3.5 in. or 89 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, for which the printer has type, may be used ( $\times$ ,  $\circ$ ,  $\bullet$ ,  $\square$ ,  $\blacksquare$ ,  $\triangle$ ,  $\blacktriangle$ ,  $\odot$ ). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

**Galley proof.** The cost of all changes on galley proof, other than printer's errors, will be charged to authors. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves. Authors receive 25 reprints free; information about ordering additional reprints will be mailed with galley proof.